MY NAME IS JOE ALIBERTI
I AM A SENIOR SCIENCE ADVISOR IN
THE OFFICE OF AIDS RESEARCH AND
THE EMCEE FOR THE NIH WORLD AIDS
DAY 2022 VIRTUAL EVENT. THIS
YEAR'S TOPIC IS PROGRESS AND
PROMISE IN HIV RESEARCH. THANK
YOU FOR JOINING US TODAY.
I WANT TO WELCOME ALL OUR
VIEWERS AND, IN PARTICULAR, OUR
DISTINGUISHED SPEAKERS,
MODERATOR, AND PANELISTS.
TODAY'S EVENT IS OPEN TO THE
GENERAL PUBLIC AND IS BEING
VIDEOCAST LIVE; THE EVENT WILL
ALSO BE RECORDED FOR LATER
VIEWING.
WE WILL HAVE A PUBLIC Q&A
FOLLOWING TODAY'S PANEL
DISCUSSION.
PLEASE SUBMIT YOUR QUESTIONS
USING THE LIVE FEEDBACK BUTTON
DIRECTLY BENEATH THE VIDEO
WINDOW BY 2:10 PM ET.
TO OPEN TODAY'S PROGRAM, I NOW
WILL INTRODUCE DR. MAUREEN
GOODENOW, WHO IS THE ASSOCIATE
DIRECTOR FOR AIDS RESEARCH AND
THE DIRECTOR OF THE OFFICE OF
AIDS RESEARCH AT NIH. DR.
GOODENOW, THE FLOOR IS YOURS.
THANK YOU AND GOOD DAY AND
WELCOME.
ON BEHALF OF OUR PARTNERS, THANK
YOU FOR JOINING US TO OBSERVE
WORLD AIDS DAY 2022.
EVERY YEAR WE COME TOGETHER ON
DECEMBER 1 TO REMEMBER THE LIVES
LOST TO HIV/AIDS TO SUPPORT THE
MILLIONS WHO CURRENTLY LIVE WITH
HIV WORLDWIDE AND WHAT NEEDS TO
BE DONE TO END THE EPIDEMIC.
WORLD AIDS DAY IS A RECURRING
OPPORTUNITY TO HAVE OUR
COMMITMENT TO HIV/AIDS TO REDUCE
THE NUMBER OF INFECTIONS AND
PROVIDE A PATH TO A NEARLY
NORMAL LIFE EXPECTANCY FOR ALL
PEOPLE WITH HIV.
IN 2021, APPROXIMATELY 38
MILLION PEOPLE WERE LIVING WITH
HIV AND 1.5 MILLION BECAME NEWLY
INFECTED WITH HIV GLOBALLY.
IN THE UNITED STATES, THERE WERE
1.2 MILLION PEOPLE WITH HIV IN
2020 AND APPROXIMATELY 31,000
PEOPLE RECEIVED A NEW HIV
DIAGNOSIS THAT YEAR.
THE LATEST HIV STATISTICS ARE
ALARMING PARTICULARLY AT A TIME
WHEN HIGHLY INFECTED ANTRI
RETROVIRALS CAN DRASTICALLY
REDUCE VIRAL LOAD OR
UNTRANSMITTABLE AND PREP IS 99%
EFFECTIVE IN PROTECTING PEOPLE
FROM SEXUAL ACQUISITION OF HIV.
THESE UNDER SCORE THE NEED TO
ENSURE EQUITABLE ACCESS TO HIV
TREATMENT AND PREVENTION
ADVANCES.
THIS YEAR, THE U.S. GOVERNMENT'S
WORLD AIDS DAY THEME FOCUSES ON
ACHIEVING EQUITY TO END HIV.
AND ON THE FUNDAMENTAL
PRINCIPLES OF ACCOUNTABILITY AND
ACTION.
THE BIDEN-HARRIS ADMINISTRATION
RENEWED ITS COMMITMENT TO ENDING
THE HIV EPIDEMIC IN THE UNITED
STATES THROUGH ITS SUPPORT TO
EQUITABLE HEALTH ACCESS AND
COMMUNITY ENGAGEMENT IN 57
PRIORITY JURISDICTIONS IN THE
UNITED STATES COMPRISED OF 48
COUNTIES, WASHINGTON, D.C. AND
PUERTO RICO THAT ACCOUNT FOR
MORE THAN HALF THE NEW HIV
DIAGNOSES AND SEVEN STATES WITH
A SUBSTANTIAL RURAL HIV HEALTH
BURDEN.
EXACTLY ONE YEAR AGO TODAY WE
WELCOMED THE REVISED NATIONAL
HIV/AIDS STRATEGY WHICH PROVIDES
A ROAD MAP TO END THE HIV
EPIDEMIC IN THE UNITED STATES BY
2030.
IN AUGUST, 2022, THE WHITE HOUSE
RELEASED THE COMPANION FEDERAL
IMPLEMENTATION PLAN WHICH
OUTLINES SPECIFIC ACTIONS TO
DRASTICALLY REDUCE NEW HIV
INFECTIONS, DEVELOP NEXT
GENERATION THERAPIES AND
DISCOVER NEW STRATEGIES TO CURE
HIV.
TOGETHER WITH THE HIV STRATEGY
PLAN FOR HIV AND HIV-RELATED
RESEARCH, THESE THREE
COMPLEMENTARY FRAMEWORKS AT THE
AGENCY, DEPARTMENT AND WHITE
HOUSE LEVEL GUIDE BASIC CLINICAL
BIO MEDICAL AND BEHAVIORAL
SOCIAL SCIENCE RESEARCH
PRIORITIES.
THE NIH HIV RESEARCH AGENDA HAS
GROWN SIGNIFICANTLY IN THE 35
YEARS SINCE CONGRESS ESTABLISHED
THE OFFICE OF AIDS RESEARCH.
SINCE JOINING THE NIH MORE THAN
SIX YEARS AGO I'M RESPONDED
PARTNERSHIPS ARE ESSENTIAL TO
ACCELERATE PROGRESS TOWARDS OUR
COMMON GOAL AND END HIV.
WE HAVE MADE UNPRECEDENTED
PROGRESS IN 40 YEARS AND THE
BENEFITS OF RESEARCH HAVE
PROPELLED THE PROGRESS FOR HIV
AND OTHER CHALLENGES SUCH AS
COVID-19 VACCINES AND
TREATMENTS.
THIS WAS POSSIBLE THROUGH
INNOVATIVE NIMBLE RESPONSES,
CREATIVITY AND RESILIENCE OF OUR
PARTNERS AND DETERMINATION BY
ALL TO BE PART OF THE SOLUTIONS.
IT IS ESSENTIAL TO MAINTAIN OUR
FOCUS AND OUR COMMITMENT
ALLOWING THE HIV EPIDEMIC TO
REBOUND WOULD BE CAT --
CATASTROPHIC FOR THE OVER ALL
STATE OF GLOBAL HEALTH IN THE
21st CENTURY.
OUR PANEL IS A REMARK ABLE
GROUP OF INDIVIDUALS WHO WILL
SHARE IDEAS ON IMPLEMENTING A
COMPREHENSIVE, HOLISTIC APPROACH
ESSENTIAL TO GENERATE HIV
RESEARCH WITH SIGNIFICANT PUBLIC
HEALTH IMPACT TO END THE HIV
PANDEMIC.
TO START THE 2022 NIH WORLD
AIDS DAY COMMEMORATION, WE ARE
HONORED TO HAVE FOUR GUEST
SPEAKERS THAT WILL OFFER
PRE-RECORDED REMARKS."
OUR FIRST SPEAKER IS
CONGRESSWOMAN BARBARA LEE, FIRST
ELECTED TO CONGRESS IN 1998, SHE
REPRESENTS CALIFORNIA'S 13TH
CONGRESSIONAL DISTRICT.
REPRESENTATIVE LEE IS CO-CHAIR
AND CO-FOUNDER OF THE BIPARTISAN
CONGRESSIONAL HIV/AIDS CAUCUS
AND HAS LEVERAGED THIS POWERFUL
POSITION TO SUPPORT IMPORTANT
HIV RESEARCH, PREVENTION, AND
EDUCATION INITIATIVES.
VERY RELEVANT TO OUR
DISCUSSIONS TODAY IS THAT, AS
CO-CHAIR OF THE CONGRESSIONAL
HIV/AIDS CAUCUS, REP. LEE
RECENTLY REINTRODUCED A
BIPARTISAN RESOLUTION TO
MODERNIZE CRIMINAL JUSTICE LAWS
THAT CRIMINALIZE HIV INFECTION.
THESE OUTDATED LAWS HAVE A
NEGATIVE EFFECT ON THE NATIONAL
EFFORT TO END THE HIV EPIDEMIC
AND ARE ONE OF THE PRIMARY
REASONS WHY PEOPLE WITH HIV DO
NOT SEEK MEDICAL CARE.
WE WELCOME REPRESENTATIVE
LEE'S MESSAGE TO WORLD AIDS DAY
2022.
>>HELLO.
I'M CONGRESSWOMAN BARBARA LEE.
THIS YEAR WE CELEBRATE AIDS DAY.
I HAVE ALWAYS MADE HIV AND AIDS
A PRIORITY.
THROUGH DECADES OF STRONG
BIPARTISAN LEADERSHIP, WE HAVE
INCREASED PREVENTION EDUCATION,
RESEARCH AND TREATMENT FOR
PEOPLE LIVING WITH HIV/AIDS NOT
JUST IN THE UNITED STATES BUT
ACROSS THE GLOBE AND LET ME TELL
YOU WE NEVER COULD HAVE DONE
THIS WITHOUT YOU.
THANK YOU SO MUCH.
FROM THE PRESIDENT'S EMERGENCY
PLAN FOR AIDS RELIEF, TO THE RON
WHITE CARE ACT AND THE MINORITY
INITIATIVE WE HAVE RESOURCES TO
END THE EPIDEMIC.
OUR WORK HAS HAD A CLEAR IMPACT
GLOBALLY.
AIDS-RELATED DEATHS HAVE BEEN
CUT BY ALMOST TWO-THIRDS AND NEW
INFECTIONS HAVE BEEN REDUCED BY
ALMOST HALF.
OVER 23 MILLION AROUND THE WORLD
NOW HAVE ACCESS TO LIFE-SAVING
ANTIVIRAL TREATMENT BUT SUCCESS
IS NOT GUARANTEED AS WE SAW WITH
COVID.
WE HAVE MORE WORK AHEAD.
13% OF THE 1.1 MILLION
HIV-POSITIVE AMERICANS ARE
UNAWARE OF THEIR STATUS.
STIGMA AND DISCRIMINATION STILL
PREVENT TOO MANY PEOPLE FROM
SEEKING TESTING AND TREATMENT.
WE KNOW BLACK, LATINX AND THE
LGBTQ COMMUNITIES ARE
DISPROPORTIONATELY AFFECTED.
ENDING THE AIDS EPIDEMIC NOT A
QUESTION OF LACK OF SCIENTIFIC
KNOWLEDGE BUT A BATTLE AGAINST
INEQUITY, STIGMA AND
DISCRIMINATION.
WE COULD NOT ACHIEVE OUR SHARED
GOALS OF AN AIDS-FREE GENERATION
WHILE DISCRIMINATORY LAWS ARE ON
THE BOOKS AND WE HAVE TO REPEAL
POLICIES THAT ENCOURAGE AND
ALLOW LEGAL HIV DISCRIMINATION
ACT OF 2022.
THANK YOU FOR CONTINUING TO JOIN
ME IN OUR FIGHT TO REALIZE AN
AIDS-FREE GENERATION.
TOGETHER, WE CAN DISMANTLE
STRUCTURAL BARRIERS TO CARE FOR
ALL INCLUDING BLACK AND BROWN
COMMUNITIES AND ASIAN COMMUNITY
AND LGBTQ PLUS COMMUNITY.
THANK YOU AGAIN AND I APPRECIATE
BEING WITH YOU AND YOUR
LEADERSHIP IS SO IMPORTANT.
WE WOULDN'T HAVE GOTTEN THIS FAR
WITHOUT YOU.
THANK YOU.
>>NEXT WE HAVE HAROLD FIP IPZ
THE
PHILLIPS, IS THE DIRECTOR OF THE
1WHITE HOUSE OFFICE OF NATIONAL
AIDS POLICY (ONAP). AS ONAP
DIRECTOR, MR. PHILLIPS OVERSAW
THE REVISION OF THE NATIONAL
HIV/AIDS STRATEGY (NHAS) AND THE
HAS FEDERAL IMPLEMENTATION PLAN,
WHICH EFFICIENTLY INTEGRATES
DIFFERENT AREAS OF HIV RESEARCH
TO OPTIMIZE PUBLIC HEALTH
OUTCOMES.
OUTCOMES. PRIOR TO JOINING THE
WHITE HOUSE, MR. PHILLIPS WORKED
MORE THAN 20 YEARS WITH
COMMUNITIES AND FEDERAL AGENCIES
TO STRENGTHEN AND ENHANCE HIV
SERVICES, POLICIES, AND
PARTNERSHIPS ACROSS THE U.S.
AND WAS THE SENIOR HIV ADVISOR
AND CHIEF OPERATING OFFICER
(COO) OF THE ENDING THE HIV
EPIDEMIC (EHE) INITIATIVE IN THE
OFFICE OF THE ASSISTANT
SECRETARY OF HEALTH AT HHS.
LET'S LISTEN TO MR. PHILLIPS'
MESSAGE.
>>HI, I'M SO HAPPY TO BE WITH
YOU ALL TO COMMEMORATE WORLD
AIDS DAY THIS YEAR.
CELEBRATING 35 YEARS OF THE NIH
OFFICE OF AIDS RESEARCH IS AN
AMAZING ACHIEVEMENT.
THE NIH OAR AT THE FOREFRONT OF
MANAGING AND ACCORDING THE
ENTIRE AID RESEARCH PROGRAM.
HIGH PRIORITY HIV RESEARCH
FUNDED THROUGH THIS PROGRAM
CONTINUALLY LEADS TO HIV
PREVENTION, TREATMENT, CARE AND
CURE SCIENCE.
THESE ADVANCES ARE SIGNIFICANT
TO THE FIGHT AGAINST HIV/AIDS
DOMESTICALLY AND GLOBALLY.
ALONGSIDE RECOGNIZING THE
ACCOMPLISHMENTS OF NIH OAR I'D
LIKE TO RECOGNIZE THE KEY ROLE
OF DR. MAUREEN GOODENOW.
AS THE DIRECTOR OF THE NIH OAR
AND ASSOCIATE DIRECTOR FOR AIDS
RESEARCH AT NIH, DR. GOODENOW
HAS BEEN A CHAMPION OF
RESEARCH'S CRITICAL ROLE IN
EFFORTS TO END HIV IN THE
U.S. AND GLOBALLY.
ADDITIONALLY, DR. GOODENOW HAS
LED SIGNIFICANT EFFORTS TO
ELEVATE THE ROLE OF DIVERSE
VOICES INCLUDING PEOPLE WITH
LIVED EXPERIENCES INTO THE NIH
OAR RESEARCH PROCESS INCLUDING
HOLDING LISTENING SESSIONS AND
EXPANDING OPPORTUNITIES FOR
COMMUNITY EXPERTS TO SHAPE AND
INFORM NIH'S HIV RESEARCH
PRIORITIES.
NIH OAR IN COLLABORATION WITH
OTHER INSTITUTES, CENTERS AND
OFFICES AT NIH ARE KEY PARTNERS
IN THE NATIONAL HIV/AIDS
STRATEGY AND FEDERAL
IMPLEMENTATION PLAN.
IT PROMOTES A WHOLE OF SOCIETY
EFFORT AND TO END THE HIV
EPIDEMIC AND WHILE ITS
IMPLEMENTATION PLAN WILL ADDRESS
EFFORTS TO END HIV DOMESTICALLY.
THE ROLE IN THE FEDERAL EM
IMPLEMENTATION PLAN CENTERS ON
FURTHERING OUR UNDERSTANDING OF
HIV AND HIV ASSOCIATED
CONDITIONS LIKE VIRAL HEPATITIS,
MENTAL HEALTH CONCERNS AND
SUBSTANCE USE DISORDERS THROUGH
RESEARCH.
NIH-FUNDED HIV SCIENCE CONTINUES
TO LEAD TO NOVEL PREVENTION AND
TREATMENT APPROACHES.
THIS INCLUDES PROVIDING THE
KNOWLEDGE BASE TO TWO OF THE
MOST CHALLENGING BARRIBARRIERS,
STIGMA AND DISCRIMINATION.
NIH-FUNDED HIV RESEARCH SUPPORTS
OUR COLLECTIVE WORK TO ADDRESS
THE HIV-RELATED STIGMA AND
DISCRIMINATION HINDERING OUR
ABILITY TO REACH POPULATIONS
MOST IMPACTED BY THIS CONDITION.
SO TO LEARN MORE ABOUT ALL OF
OUR FEDERAL HIV PROGRAMS AND THE
NATIONAL HIV AIDS STRATEGY
PLEASE VISIT HIV.gov
>>THANK YOU FOR YOUR KIND
WORDS.
YOUR LIFE LONG COMMITMENT IN
ENDING STIGMA AND DISCRIMINATION
INSPIRES ALL OF US.
NEXT I'M PLEASED TO INTRODUCE
ADMIRAL RACHEL LEVINE.
SHE'S THE 17th ASSISTANT
SECRETARY FOR HEALTH AND LEADS
THE SERVICE HEALTH COMMISSION
CORPS.
IN HER ROLE AS ASSISTANT
SECRETARY, SHE WORKS TO IMPROVE
THE HEALTH AND WELL BEING OF ALL
AMERICANS FROM OVERCOMING THE
COVID-19 PANDEMIC TO BUILDING A
FOUNDATION FOR A HEALTHIER
AMERICA.
SHE IS A STRONG ADVOCATE FOR THE
LGBTQ COMMUNITY.
WE'RE PLEASED TO WELCOME ADMIRAL
LEVINE TO WORLD'S AIDS DAY 2022.
>>THANK YOU FOR THE KIND
INTRODUCTION.
WORLD AVEDS DAY IS AN
OPPORTUNITY TO REMEMBER THE MORE
THAN 40 MILLION PEOPLE ESTIMATED
TO HAVE DIED FROM AIDS-RELATED
ILLNESSES ACROSS THE GLOBE.
THESE LOSSES OF OUR FRIENDS,
FAMILY MEMBERS AND OTHERS
WORLDWIDE ARE HEARTBREAKING.
AND WE HONOR THEIR MEMORIES.
HOWEVER, WE HAVE MADE PROGRESS
IN OUR FIGHT TO END THE HIV
EPIDEMIC.
THE WORK OF THE NIH HAS FUELED
OUR PROGRESS WHICH CONTINUES TO
BE VITAL TO ACHIEVING OUR
NATIONAL GOAL OF ENDING THE HIV
EPIDEMIC BY 2030.
I AM DEEPLY GRATEFUL FOR YOUR
DEDICATION, YOUR CREATIVITY AND
YOUR COMMITMENT.
TODAY EVENT INCLUDES ALL FROM
SOCIETY DEMONSTRATING A WHOLE OF
SOCIETY APPROACH TO END THE HIV
EPIDEMIC.
THIS COMMITMENT IS REFLECTED IN
THIS YEAR'S WORLD AIDS DAY
THEME, PUT OURSELVES TO THE
TEST.
ACHIEVING EQUITY TO END HIV.
THIS THEME EMPHASIZES
ACCOUNTABILITY AND ACTION.
IT AFFIRMS THE ADMINISTRATION'S
DEDICATION TO ENDING HIV IN ITS
COMMITMENT TO EQUITY CENTERING
ON THE ENGAGEMENT OF THOSE WITH
LIVED EXPERIENCES PARTICULARLY
IN COMMUNITIES THAT ARE
DISPROPORTIONATELY IMPACTED.
AS WE PUT OURSELVES TO THE TEST,
IT WILL TAKE EVERYONE'S
COMMITMENT TO SUCCESSFULLY END
HIV.
MY COMMITMENT BEGAN DURING THE
EARLY DAYS OF THE HIV EPIDEMIC
WHILE WORKING IN NEW YORK CITY.
AS YOU CAN IMAGINE THAT
EXPERIENCE INFORMED MY PERSONAL
COMMITMENT TO SEE AN END TO THIS
EPIDEMIC.
I KNOW THAT'S NOW POSSIBLE DUE
TO ADVANCES IN HIV RESEARCH.
WE HAVE SEEN REMARKABLE
CONTRIBUTIONS FROM THE RESEARCH
COMMUNITY INCLUDING PREP AND THE
DISCOVERY THAT PEOPLE WITH HIV,
WHO ARE ON ANTIVET --
ANTIRETROVIRAL THERAPY WILL NOT
TRANSMIT AND UNDETECTABLE EQUALS
UNTRANSMITTABLE.
THIS HAS TRANSFORMED LIVES.
HOWEVER, MORE EDUCATION IS
NEEDED ABOUT THE IMPACT OF
HAVING AN UNDETECTABLE VIRAL
LOAD.
PLEASE CHECK OUT HIV.gov TO
LEARN ABOUT THE I AM A WORK OF
ART VIRAL SUPPRESSION CAMPAIGN.
ALL THESE EFFORTS HAVE MOVED US
FORWARD.
HOWEVER, WE MUST CONTINUE TO
ADDRESS THE ROLE OF HIV STIGMA
AND THE ROLE THAT PLAYS IN
HINDERING OUR WORK TO ENSURE THE
ADVANCES THAT WE HAVE MADE REACH
THOSE MOST IMPACTED BY THIS
EPIDEMIC AND INCLUDING THEM IN
THE PROCESS.
THIS WAS REINFORCED FOR ME AT
THE INTERNATIONAL AIDS
CONFERENCE THIS SUMMER WHERE I
MET WITH RESEARCHERS AND OTHERS.
I WAS STRUCK BY THEIR COMMITMENT
TO INCLUDE COMMUNITY ADVOCACIES
AND PEOPLE OF LIVED EXPERIENCES
IN A COLLABORATIVE RESEARCH
PROCESS.
THIS COMMITMENT WAS ALSO EF OF
THE NIH COORDINATED BY THE NIH
OFFICE OF AIDS RESEARCH AND THE
NATIONAL HIV/AIDS STRATEGY
RELEASED LAST YEAR BY PRESIDENT
BIDEN.
IT PROVIDES A ROAD MAP FOR
STAKEHOLDERS TO END THE HIV
EPIDEMIC.
NIH COLLEAGUES WERE ALSO
CRITICAL TO DEVELOPMENT OF THE
STRATEGY'S COMPANION DOCUMENT
THE FEDERAL IMPLEMENTATION PLAN.
IT DOCUMENTS FROM AGENCIES'
COMMITMENTS TO PROGRAMS,
POLICIES AND RESEARCH FOR 2022
TO 2025 TO MEET THE STRATEGY'S
GOALS.
IN CLOSING, I WAS HERE AT THE
BEGINNING OF THE EPIDEMIC, AND I
WANT TO BE HERE AT ITS END.
I OUR PATH THIS GOAL HAS BEEN
LAID BY THE POWERFUL
CONTRIBUTIONS OF DR. ANTHONY
FAUCI.
WE ALL OWE HIM OUR GRATITUDE AND
WISH HIM WELL IN HIS FUTURE
ENDEAVORS AS HE STEPS DOWN FROM
HIS CURRENT POSITIONS LATER THIS
MONTH.
I AM PLEASED YOU WILL ALL BE
HEARING FROM HIM TODAY.
THANK YOU.
>>THANK YOU SO MUCH, ADMIRAL
LEVINE FOR THOSE WONDERFUL
REMARKS.
AND NOW IT IS WITH GREAT
PLEASURE THAT I INTRODUCE THE
NEXT SPEAKER, DR. ANTHONY FAUCI.
I SPEAK FOR ALL WHEN I SAY THAT
THE NATION APPRECIATED HIS
CLARITY OF MIND AND MESSAGES
DURING THE COVID-19 PANDEMIC, AS
WELL AS WITH PREVIOUS PUBLIC
HEALTH RESPONSES TO SARS, MERS,
AND EBOLA BETWEEN 2003 AND 2016.
BUT THE HIV PANDEMIC THAT
STARTED 41 YEARS AGO HAD ALREADY
TESTED DR. FAUCI'S SKILLS.
NOTHING MARKED HIS PERSONAL AND
PROFESSIONAL TRAJECTORY MORE
THAN THE IDENTIFICATION OF THE
HUMAN IMMUNODEFICIENCY VIRUS IN
THE FIRST COHORT OF PATIENTS
AFFECTED BY THE ACQUIRED
IMMUNODEFICIENCY SYNDROME (AIDS)
IN THE EARLY 1980'S. DR. FAUCI
BECAME DIRECTOR OF NIAID IN 1984
AND WAS THE FOUNDING DIRECTOR OF
THE OFFICE OF AIDS RESEARCH,
WHICH HE LED FROM 1988, WHEN OAR
WAS ESTABLISHED BY CONGRESS,
UNTIL 1994.
DR. FAUCI WAS ONE OF PEPFAR
KEY ARCHITECTS, A PROGRAM WITH
AN UNPARALLELED GLOBAL IMPACT.
AMONG HIS MANY HONORS, HE IS A
RECIPIENT OF THE PRESIDENTIAL
MEDAL OF FREEDOM AND A MEMBER OF
THE NATIONAL ACADEMY OF SCIENCES
AND THE NATIONAL ACADEMY OF
MEDICINE.
AND AND SPECIAL ADVISER TO SEVEN
U.S. PRESIDENTS.
LET'S LISTEN TO HIS UNIQUE
PERSPECTIVES ON THE ROAD
TRAVELED TO ARRIVE AT WORLD AIDS
DAY, 2022.
>>GREETINGS, EVERYONE.
THIS IS TONY FAUCI AT NIAID AND
A PLEASURE TO SPEAK TO YOU AT
THE WORLD AIDS DAY ENVIRONMENT
EVENT.
WE CAN LOOK TO THE PROGRESS MADE
IN HIV RESEARCH AND STILL
REALIZE THE NEED FOR MORE
ADVANCES.
FOUR DECADES OF AIDS HAVE BEEN
PUNCTURED BY PERIODS OF DARKNESS
AND HOPE.
IN THE EARLY FRUSTRATING DAYS OF
THE PANDEMIC, WE HAD LITTLE TO
OFFER OUR PATIENTS.
THE GLIMERS OF HOPE CAME WITH
TREATMENT AND THE FIRST
PARTIALLY EFFECTIVE AN
ANTIRETROVIRAL DRUGS AND IT
TRANSFORMED THE DIAGNOSES AND
NOW NOW THERE'S A SINGLE DAILY
PILL.
LOOKING BACK TO WHEN I WAS NAMED
THE FIRST OAR DIRECTOR IN 1988,
WE HAD FEW TOOLS TO TREAT
PATIENTS WITH HIV AND ONLY ONE
LICENSE ANTIRETROVIRAL DRUG AZT
AND A PERSON DIAGNOSED HAD A
LIFE EXPECTANCY OF LESS THAN 3
YEARS.
TODAY A PERSON WITH HIV CAN
EXPECT TO LIVE AN ALMOST NORMAL
LIFE SPAN.
A CRUCIAL LESSON IS THERAPY
HELPS THE PERSON LIVING WITH HIV
AND GREATLY REDUCE THE RISK OF
TRANSMITTING IT TO OTHERS.
THE UNDETECTABLE EQUALS
UNTRANSMISSIBLE HAS BEEN A
DRIVING INFLUENCE IN EVERY PHASE
OF THIS JOURNEY.
ALSO TRANSFORMATIVE IS
PRE-EXPOSURE PROPHYLAXIS OR PREP
WHICH CAN BE MORE THAN 99%
EFFECTIVE IN PROTECTING PEOPLE
FROM SEXUAL ACQUISITION OF HIV.
DRAWING LESSONS FROM THE CURRENT
COVID-19 PANDEMIC, I SUSPECT
MONOCLONAL ANTIBODIES WILL SOON
PLAY A ROLE IN TREATING AND
PREVENTING HIV AS THEY HAVE FOR
SARS COV2.
MEDICAL ADVANCES MEAN HIV/AIDS
COULD THEORETICALLY NOW BE TAKEN
OFF THE TABLE AS A MAJOR HEALTH
THREAT BOTH IN THE UNITED STATES
AND GLOBALLY PARTICULARLY FOR
PROGRAMS SUCH AS ENDING THE HIV
EPIDEMIC IN THE UNITED STATES OR
EHE AS WE CALL IT, THE
PRESIDENT'S EMERGENCY PLAN FOR
AIDS RELIEF, PEPFAR AND THE
GLOBAL FUND TO FIGHT AIDS,
TUBERCULOSIS AND MALARIA
CONTINUE TO RECEIVE ROBUST
SUPPORT.
SADLY, THINGS HAVE NEVER THAT
SIMPLE IN PRACTICE.
UPTAKE IN RETENTION OF
TREATMENTS REMAINS SUB OPTIMAL.
IN RICH COMMUNITIES AS WELL AS
IN POOR ONES.
THE REASONS INCLUDE A LACK OF
TRANSPORTATION, SUBOPTIMAL
HOUSING, MENTAL HEALTH ISSUES,
SUBSTANCE ABUSE, PILL FATIGUE,
DRUG TOXICITY, STIGMA AND
DISCRIMINATION AND MORE.
AND SO A TOP PRIORITY STO ENSURE
THAT EVERYONE HAS ACCESS TO
EXISTING TREATMENT AND
PREVENTION OPTIONS WHILE WE
DEVELOP BETTER ONES.
WE HAVE CAUSE FOR OPTIMISM AS
NEW INTERVENTIONS COME ONLINE.
THE FIRST LONG-ACTING INJECTABLE
ANTIRETROVIRAL REGIMENTS AND AN
INJECTABLE LONG-ACTING FORM FOR
PREVENTION ARE POTENTIALLY
TRANSFORMATIVE.
EXCITING WORK IS UNDERWAY FOR
FURTHER HIV TREATMENT AND
PREVENTION OPTIONS.
THESE INCLUDE VERY LONG ACTING
DRUGS THAT COULD BE TAKEN ONCE
EVERY SIX MONTHS OR EVEN LESS
FREQUENTLY.
AND THEN THERE ARE STRATEGIES TO
ACHIEVE DURABLE HIV REMISSION.
ONE, IS ERADICATING THE HIV
COMPETENT RESERVOIR REFERRED TO
AS A CLASSIC CURE.
OTHER APPROACHES SEEK TO CONTROL
THE VIRUS THROUGH A MEANS
BESIDES DAILY ANTIRETROVIRALS.
OFTEN REFERRED TO AS SUSTAINED
VIROLOGICAL REMISSION.
THE DEVELOPMENT OF A SAFE AND
EFFECTIVE HIV VACCINE HAS BEEN
ELUSIVE SO FAR IN THE 40-YEAR
JOURNEY.
EVEN A MODERATELY EFFECTIVE
VACCINE COULD TOGETHER WITH THE
REST OF THE TOOL KIT BRING AN
END TO AIDS AS A MAJOR HEALTH
CONCERN.
MANY APPROACHES ARE BEING
TESTED.
LIKELY SOME OF THE TOOLS AND
PLATFORMS USED FOR COVID-19
VACCINES CAN BE ADAPTED FOR HIV
VACCINES INCLUDING mRNA AND
OTHER PLATFORMS.
ENDING THE HIV PANDEMIC IS AN
AMBITIOUS BUT FEASIBLE GOAL.
TOGETHER, WE MUST RECOMMIT TO
OPTIMALLY IMPLEMENTING THE MANY
EVIDENCE-BASED TOOLS WE HAVE TO
PREVENT AND TREAT HIV.
NEW APPROACHES TO HIV TREATMENT
AND PREVENTION INCLUDING
LONG-ACTING TREATMENTS, NOVEL
HIV VACCINE ANTIGENS AND WHAT
PRODUCES NATURALLY PRODUCING
ANTIBODIES AND OTHER CONCEPTS
FOR HIV VACCINE ALL MUST BE
REFINED, DEVELOPED AND TESTED.
AND WE MUST RE-ENGAGE AND
STRENGTHEN OUR COALITION TO
INCLUDE A ROBUST AND DIVERSE
CADRE OF NEXT GENERATION HIV
INVESTIGATORS AND COMMUNITY
PARTNERS ACROSS THE UNITED
STATES AND AROUND THE WORLD TO
ASSURE THAT OUR EFFORTS WILL
REACH ALL AND WILL ENDURE.
WITH RE-INVIGORATED DEDICATION
TO OUR COLLABORATIVE GOAL, WE
CAN AND WILL ULTIMATELY CLOSE
THE BOOK ON THE HIV PANDEMIC.
THANK YOU.
>>THANK YOU, DR. FAUCI FOR YOUR
INSPIRATIONAL REMARKS [A
SENTENCE ECHOING HIS MESSAGE MAY
BE INSERTED HERE]
AND FOR REMINDING US IT'S A
FEASIBLE GOAL.
NOW TO TURN IT BACK TO JULIO
ALIBERTI TO INTRODUCE OUR
DISTINGUISHED GUESTS DR. HODDER
TO MODERATE THE PANEL SESSION.
OVER TO YOU.
>>THANK YOU, DR. GOODENOW.
I WOULD LIKE TO REMIND THOSE
WHO ARE WATCHING THAT YOU ARE
INVITED TO SUBMIT QUESTIONS FOR
THE QUESTION AND ANSWER SESSION
THAT WILL FOLLOW THE PANEL
DISCUSSION. PLEASE SUBMIT ANY
QUESTIONS BY CLICKING ON THE
LIVE FEEDBACK BUTTON BELOW THE
VIDEO WINDOW BY 2:10 P.M. ET.
I AM HONORED TO INTRODUCE OUR
PANEL MODERATOR, DR. SALLY
HODDER. DR. HODDER IS A SEASONED
INFECTIOUS DISEASES PHYSICIAN
WITH EXTENSIVE HIV RESEARCH
EXPERIENCE. SHE IS THE ASSOCIATE
VICE PRESIDENT FOR CLINICAL AND
TRANSLATIONAL SCIENCE AND
DIRECTOR AT THE WEST VIRGINIA
CLINICAL AND TRANSLATIONAL
SCIENCE INSTITUTE AT WEST
VIRGINIA UNIVERSITY. SHE SERVES
AS THE PRINCIPAL INVESTIGATOR ON
SEVERAL NIH-FUNDED U AWARDS AND
THE PROTOCOL CHAIR FOR A LARGE
NIH-SUPPORTED TRIAL IN THE AREA
OF HIV PREVENTION.
I'D LIKE TO WELCOME OUR
PANELISTS.
SXP
I ALSO WELCOME OUR PANELISTS:
DR. JONATHAN APPELBAUM, FROM
FLORIDA STATE UNIVERSITY
OF
FLORIDA STATE UNIVERSITYDR.
APPELBAUM IS THE LAURIE L.
DOZIER, JR., M.D., EDUCATION
DIRECTOR AND PROFESSOR OF
INTERNAL MEDICINE AT FLORIDA
STATE UNIVERSITY COLLEGE OF
MEDICINE, WHERE HE ALSO SERVES
AS THE CHAIR OF THE DEPARTMENT
OF CLINICAL SCIENCES. HIS
RESEARCH INTERESTS FOCUS ON
LGBTQ+ HEALTH DISPARITIES AND
AGING AND HIV.
1K7
DR. BROWN IS AN ASSOCIATE
PROFESSOR OF NEUROLOGY AT THE
JOHNS HOPKINS UNIVERSITY SCHOOL
OF MEDICINE. HER RESEARCH AIMS
TO ANSWER FUNDAMENTAL QUESTIONS
ABOUT THE INFLAMMATORY RESPONSE
AND HOMEOSTATIC SIGNALING AFTER
HIV-1 INFECTION AND INJURY TO
THE NERVOUS SYSTEM AND THE
LONG-TERM IMPACTS ON NEUROLOGIC
FUNCTION.
FUNCTION. DR. SANDRA MCCOY,
FROM THE UNIVERSITY OF
CALIFORNIA, BERKELEY
?DR. MCCOY IS A PROFESSOR IN
THE DIVISION OF EPIDEMIOLOGY AT
THE UNIVERSITY OF CALIFORNIA,
BERKELEY SCHOOL OF PUBLIC
HEALTH. HER STUDIES FREQUENTLY
FOCUS ON INCREASING UTILIZATION
OF SERVICES AND PRODUCTS LIKE
HIV SELF-TESTING, HIV TREATMENT
AND CARE, AND PRE-EXPOSURE
PROPHYLAXIS (PREP).
PROPHYLAXIS (PREP).DR. CARLOS
RODRIGUEZ-DIAZ, FROM GEORGE
WASHINGTON UNIVERSITY
WASHINGTON UNIVERSITYDR.
RODRIGUEZ-DIAZ IS AN ASSOCIATE
PROFESSOR AND VICE CHAIR OF THE
DEPARTMENT OF PREVENTION AND
COMMUNITY HEALTH AT THE MILKEN
INSTITUTE SCHOOL OF PUBLIC
HEALTH AT GEORGE WASHINGTON
UNIVERSITY. HIS WORK HAS FOCUSED
ON HEALTH EQUITY THROUGH ACTIONS
ON THE SOCIAL DETERMINANTS OF
HEALTH, WITH SPECIAL ATTENTION
TO LATINO COMMUNITIES, SEXUAL
AND GENDER MINORITY POPULATIONS,
AND PEOPLE AFFECTED BY HIV AND
OTHER SEXUALLY TRANSMITTED
INFECTIONS.
INFECTIONS.MS. DAFINA WARD,
MS. WARD IS EXECUTIVE DIRECTOR
OF THE SOUTHERN AIDS COALITION.
THE MISSION OF SAC IS TO END THE
HIV AND STI EPIDEMICS IN THE
SOUTH BY PROMOTING ACCESSIBLE
AND HIGH-QUALITY SYSTEMS OF HIV
AND STI PREVENTION, TREATMENT,
CARE, HOUSING, AND ESSENTIAL
SUPPORT SERVICES.
DR. HODDER, THE FLOOR IS YOURS.
>>THANK YOU VERY MUCH FOR THAT
KIND INTRODUCTION.
AND THANK ALL YOU FOR ATTENDING
THIS EVENT AND PARTICULARLY TO
MY DISTINGUISHED PANELISTS HERE
TODAY
OVER 40 YEARS AGO, THE DISCOVERY
OF THE HUMAN IMMUNODEFICIENCY
VIRUS (HIV) CHALLENGED
SCIENTISTS AND POLICYMAKERS TO
WORK TOGETHER ON ACQUIRED
IMMUNODEFICIENCY SYNDROME
(AIDS), WHICH WAS THEN AN
UNTREATABLE, FATAL DISEASE.
TODAY, EFFORTS BY THE HIV/AIDS
COMMUNITY AND RESEARCHERS, AS
WELL AS GOVERNMENT INITIATIVES
SUCH AS ENDING THE HIV EPIDEMIC
IN THE U.S., THE U.S.
PRESIDENT'S EMERGENCY PLAN FOR
AIDS RELIEF, AND THE NATIONAL
HIV/AIDS STRATEGY, ARE TURNING
RESEARCH INTO ACTION THAT GIVES
PEOPLE ACCESS TO LIFESAVING AND
LIVE-IMPROVING RESOURCES FOR HIV
PREVENTION, DIAGNOSIS, AND
TREATMENT. AS WE HEARD FROM OUR
OPENING SPEAKERS, CONTINUING
THIS MOMENTUM WILL REQUIRE A
CROSS-SECTOR AND
CROSS-DISCIPLINARY APPROACH TO
HIV/AIDS RESEARCH.
HIV/AIDS RESEARCH.THE PAST
THREE YEARS HAVE INTRODUCED A
NEW RANGE OF CHALLENGES FOR THE
HIV RESEARCH COMMUNITY AS
RESEARCHERS HAVE HAD TO RESPOND
SIMULTANEOUSLY TO THE COVID-19
AND HIV PANDEMICS.
AS WE HEARD FROM OUR OPENING
SPEAKERS TODAY, CONTINUING THIS
MOMENTUM WILL REQUIRE A
CROSS-SECTOR AND
ACROSS-DISCIPLINARY APPROACH TO
HIV RESEARCH.
OVER THE PAST THREE YEARS, THE
CORONAVIRUS PANDEMIC HAS
INTRODUCED A NEW RANGE OF
CHALLENGES FOR EVERYONE AND FOR
THE HIV RESEARCH COMMUNITY.
INVESTIGATORS HAVE HAD TO
RESPONSE SIMULTANEOUSLY TO
COVID-19 AND TO THE HIV
PANDEMIC.
IMPORTANTLY, HIV RESEARCH HAS
INFORMED SOCIETY'S RESPONSE TO
COVID-19 WHICH IN TURN HAS SHOWN
US HOW RESEARCH CAN BE PUSHED
FORWARD TO DELIVER RAPID
RESULTS.
SEVERAL OTHER KEY THEMES HAVE
EMERGED TO GUIDE FUTURE EFFORTS
TO BUILD ON THE PROGRESS WE HAVE
MADE TO DATE.
DURING THE CORONAVIRUS PANDEMIC,
SEVERAL HIV RESEARCHERS SHIFTED
THEIR FOCUS TO STUDYING AND
COMBATTING COVID-19 AND THEIR
EFFORTS HAVE DEMONSTRATED THE
POTENTIAL FOR HIV RESEARCHERS TO
SOLVE PROBLEMS ACROSS SCIENTIFIC
AREAS.
BUT WE NEED TO SUPPORT AND
NURTURE THE NEXT GENERATION OF
INVESTIGATORS AS WELL AS THE
NEXT GENERATION OF ADVOCATES AND
PROVID
PROVIDERS.
MOREOVER THE PANDEMIC
HIGHLIGHTED INEQUITIES, INACCESS
TO CARE AND NOW IS THE KEY
MOMENT TO USE INNOVATIVE
APPROACHES TO ADDRESS THE
PROBLEM.
A FACET OF THE HIV PANDEMIC IS
THE GROWING AGING POPULATION OF
PEOPLE LIVING WITH HIV.
WE THESE TO EXPLORE THE KEY
RESEARCH GAPS THAT AFFECT THIS
POPULATION AND SEEK SOLUTIONS.
THE INTERSECTION OF THE HIV AND
OPIOID EPIDEMICS IS A VERY
SERIOUS PROBLEM AND WE REALLY
NEED TO FACE THE SERIES OF
CHALLENGES THAT IN MY OPINION
ARE CRITICALLY IMPORTANT AND
REQUIRE MUCH GREATER ATTENTION
FROM OUR RESEARCH COMMUNITY.
AND FINALLY
RECENT EXPERIENCE HAS UNDERLINED
THE ESSENTIAL ROLE THAT MEMBERS
OF THE COMMUNITY AND ADVOCATES
CAN PLAY IN PROVIDING INPUT ON
HIV/AIDS RESEARCH, FROM CONCEPT
DEVELOPMENT TO IMPLEMENTATION.
TAKING ALL OF THIS INTO ACCOUNT,
WE CAN ADVANCE HIV RESEARCH BY
SUPPORTING A MORE INTEGRATED
APPROACH, INCLUDING:
APPROACH, INCLUDING:GOING "BACK
TO BASICS" (SUCH AS BASIC
BIOMEDICAL AND BASIC BEHAVIORAL
AND SOCIAL SCIENCES RESEARCH).
IMPORTANT TO HIV RESEARCH AND
OTHER AREAS.
1APPLYING TRANSFORMATIVE TOOLS
(SUCH AS NEW TECHNOLOGIES,
METHODOLOGIES, AND
IMPLEMENTATION SCIENCE
APPROACHES).
APPROACHES).EXAMINING HIV
WITHIN THE CONTEXT OF
CO-OCCURRING CONDITIONS (IN THE
CONTEXT OF THE LIFE COURSE OR
ALONGSIDE VARYING SOCIAL
DETERMINANTS OF HEALTH,
INCLUDING SUBSTANCE USE).
STRENGTHENING CAPACITY (SUCH AS
DIVERSITY/WORKFORCE, ESI,
RESEARCH RECOVERY,
INFRASTRUCTURE).
INFRASTRUCTURE).I'M THRILLED TO
BE HERE TODAY WITH A
DISTINGUISHED PANEL OF GUESTS TO
DIVE INTO THESE TOPICS IN
DETAIL.
DETAIL. PANELISTS, AS A
REMINDER, PLEASE LEAVE YOUR
CAMERAS ON FOR THE DURATION OF
THE DISCUSSION.
LET'S START PERHAPS WITH
DR. BROWN WHO HAS REALLY DONE
WONDERFUL WORK WITH EARLY STAGE
INVESTIGATORS.
WHAT RECOMMENDATIONS DO YOU HAVE
FOR REALLY PROMOTING AND
RECRUITING THE NEXT GENERATION
OF HIV RESEARCHERS?
>>THANK YOU, DR. HODDER AND
IT'S AN HONOR TO BE HERE IN SUCH
DISTINGUISHED GUESTS AND OUR
HEROES IN THE FIELD AND SO WE
NEED TO CONTINUE TO NURTURE AT
ALL LEVELS OF TRAINING AT THE
HIGH SCHOOL LEVEL, UNDERGRADUATE
LEVEL, OF COURSE THE GRADUATE
LEVEL AND BEYOND.
AND THE NIH HAS REALLY DONE THIS
SO WELL AND THINKING ABOUT THIS
THEME FOR OUR NIH AIDS WORLD DAY
RECOGNITION OF EQUITY AND
ACCESSIBILITY AND ACTION.
IT'S REALLY ON OUR END DOCK THE
JOB OF FINDING THESE INDIVIDUALS
COME FROM DIVERSE BACKGROUNDS
THAT BRING THE NOVEL INNOVATIVE
IDEAS AND SOLUTIONS AND MAKING
SURE THAT THEY FEEL AND KNOW
THAT THEY MUST BE INCLUDED IN
THIS ENTERPRISE.
AND SO FOR EXAMPLE, I WORKED IN
THIS INTERDISCIPLINARY SPACE
BETWEEN THE NERVOUS SYSTEM AND
THE IMMUNE SYSTEM.
AND SO IN THE NEUROSCIENCES, FOR
EXAMPLE, ONLY ABOUT 2% TO 4% OF
FACULTY LEVEL INVESTIGATORS COME
FROM BACKGROUNDS SUCH AS MINE.
AND SO THESE NIH RESEARCH-FUNDED
PROGRAMS THAT PROVIDE ON THE
GROUND EXPERIENCES FOR YOUNG
PEOPLE TO NETWORK WITH FACULTY
SCIENTISTS, NEUROLOGISTS, OTHERS
IN THE BIOMEDICAL RESEARCH
WORKFORCE THAT ARE DOING THIS
WORK TOWARDS FINDING A SOLUTION
AND A CURE FOR HIV.
THEY GET THE OPPORTUNITY TO
ACTUALLY SEE FIRST HAND TO BUILD
THEIR PROFESSIONAL NETWORK BUT
IMPORTANTLY TO GET EXCITED ABOUT
RESEARCH TO LEARN THE SCIENTIFIC
METHOD IN A COLLABORATIVE
MENTORED RELATIONSHIP.
AND SO THIS IS EXTREMELY
IMPORTANT THAT WE CONTINUE THIS
WORK.
>>THANK YOU, DR. BROWN.
IT'S SO IMPORTANT THAT VERY
EARLY STAGE AND I LIKE THE FACT
THAT YOU REFLECTED BACK TO NOT
JUST STARTING AS A JUNIOR
FACULTY MEMBER BUT STARTING AT
HIGH SCHOOL AND COLLEGE AND THE
PROMISE OF EXCITING SCIENCE.
DR. RODRIGUEZ-DIAZ WOULD YOU
LIKE TO ADD WHAT NEEDS TO BE
DONE FOR RECRUITMENT AND SUPPORT
OF THE NEXT GENERATION OF
RESEARCHERS AND THE NEXT
GENERATION OF PROVIDERS AND
ADVOCATES?
>>THANK YOU FOR THE OPPORTUNITY
TO JOIN THIS PANEL.
I AM HONORED TO BE PART OF THIS
CONVERSATION.
I AGREE WITH DR. BROWN.
I WILL ADD THAT WE NEED TO
UNDERSTAND THAT STRUCTURAL
RACISM AFFECTS THE EXPERIENCES
THAT MANY PEOPLE OF COLOR HAVE
IN THEIR OWN COMMUNITIES AND
DEVELOPING AN INTEREST AND A
PORTFOLIO OF WORK EITHER
ADVOCATES, ACTIVISTS OR
SCIENTISTS FROM A SCIENTIFIC
PERSPECTIVE WE NEED TO WORK ON
THE SYSTEM THAT PROVIDES THE
RESOURCES FOR PEOPLE OF COLOR TO
WORK WITH OUR OWN COMMUNITIES.
WE NEED RESOURCES SO WE CAN
CENTER THE COMMUNITIES IN THE
RESEARCH THAT WE ARE DOING TO
HAVE A MORE COMPREHENSIVE,
RELEVANT AND SUSTAINABLE
RESEARCH AND SERVICES THAT ARE
CONSISTENT WITH THE VALUES AND
PRACTICES OF OUR COMMUNITIES.
TO GET THE FUNDING, I ENCOURAGE
ALL THE FUNDERS TO HELP PEOPLE
OF COLOR IN THE PANELS THAT ARE
REVIEWING APPLICATIONS TO
PROVIDE RESOURCES.
WE NEED PEOPLE LIKE OURSELVES
THAT UNDERSTAND OUR COMMUNITIES
TO REVIEW OUR APPLICATIONS AND
TO CRITICALLY CONTRIBUTE TO THE
SCIENTIFIC WORK WE CAN DO.
AND LASTLY, WE NEED TO CONTINUE
TO ENCOURAGE TRANS DISCIPLINARY
WORK THAT IS COMMUNITY CENTERED,
THAT INTEGRATED ACTIVISTS,
MOBILIZERS, SCIENTISTS, LEADERS
BECAUSE OUR COMMUNITY REQUIRES A
COMPREHENSIVE APPROACH AND IN
THAT WAY WE'LL ATTRACT THE YOUNG
PEOPLE FROM THE COMMUNITY, YOUNG
SCHOLARS AND OTHER MEMBERS OF
OUR COMMUNITIES WHO MAY BE
INTERESTED IN EITHER RESEARCH OR
THE PRACTICE OF PUBLIC HEALTH OR
CLINICAL CARE.
>>THANK YOU, DR
DR. RODRIGUEZ-DIAZ.
YOUR COMMENTS I THINK HIGHLIGHT
THE IMPORTANCE OF COMMUNITY
PASSION.
IT'S REALLY THE PARTICIPATION IN
THE EARLY DAYS THAT BROUGHT THE
APPROPRIATE ATTENTION TO THE
HIV/AIDS PANDEMIC AND I THINK
THEY WERE CRITICAL TO DEFINING
AND MAKING KNOWN SOME OF THE
NEEDS OF PERSONS LIVING WITH
HIV.
MS. WARD, GIVEN THE IMPORTANCE
OF COMMUNITY INVOLVEMENT IN HIV
RESEARCH, WHAT RECOMMENDATIONS
DO YOU HAVE FOR THE NIH TO
BETTER SUPPORT ENGAGEMENT OF
COMMUNITIES IN HIV RESEARCH?
>>THANK YOU SO MUCH FOR THAT
DR. HODDER AND THREW FOR NIH OAR
FOR HAVING THE PARTICIPATE IN
THE PANEL TODAY.
I RECENTLY WAS TALKING WITH A
COLLEAGUE WHO DOES A LOT OF
COMMUNITY-BASED PARTICIPATORY
RESEARCH AND SOMETHING SHE
SHARED IS THAT COMMUNITY
RESEARCH THAT DOES NOT RETURN TO
COMMUNITY IS EXPLOITATION MASKED
AS SCIENCE.
THIS IDEA THERE COULD BE
OPPORTUNITIES BY NIH TO GET THE
RESEARCH AND THE FINDINGS BACK
INTO THE HANDS OF THE
COMMUNITIES MOST IMPACTED IS
CRITICALLY IMPORTANT.
AND PRIORITIZING FUNDING AND
SUPPORTING COMMUNITY RESEARCH
THAT TRULY INCLUDES ORGANIZATION
ARE COMMUNITY BASED AND LED AND
FOUNDED BY THE COMMUNITIES MOST
MARGINALIZED AND HEAVILY
IMPACTED DISPROPORTIONATELY BY
HIV.
THOSE ARE IMPORTANT STEPS.
THERE HAS TO BE -- NIH HAS THE
PROWESS AND THE POWER AND I
THINK EVEN THE RESPONSIBILITY TO
CREATE THAT LEVEL OF COMMUNITY
THAT COMMUNITY-PARTICIPATORY
RESEARCH SHOULD GO BACK TO
COMMUNITY AND THERE'S NO ONE
BETTER SUITED TO ENCOURAGE
COMMUNITY INVOLVEMENT IN
RESEARCH TO REASSURE COMMUNITY
ABOUT THE NECESSITY AND
IMPORTANCE OF THEIR INVOLVEMENT
IN RESEARCH THAN THOSE ON THE
GROUND IN THOSE COMMUNITIES
EVERY DAY.
>>THANK YOU VERY MUCH FOR THOSE
REALLY INSIGHTFUL COMMENTS.
I WAS STRUCK AND ALL OF THEM
WERE INSIGHTFUL BUT I WAS STRUCK
BY THE FACT THAT YOU TALK ABOUT
THE IMPORTANCE FOR TAKING THOSE
RESULTS BACK AND DISCUSSING WHAT
ELSE IS NEEDED AND I WILL SAY
THAT OFTEN THAT ISN'T
CONSIDERED.
THE SCIENCE IS INITIALLY BUT
GIVING BACK TO THE COMMUNITY IS
THAT IN THE BUDGET?
USUALLY NOT.
I REALLY APPRECIATE THAT.
GOING BACK TO DR. RODRIGUEZ-DIAZ
YOU BROUGHT UP THE THEME OF
COMMUNITY.
WOULD YOU LIKE TO ADD TO MS.
BROWN'S COMMENTS?
>>SURE.
AS PART OF CHANGING THE SYSTEMS
WITH CHALLENGES, WE HAVE TO GET
CREATIVE AND CREATE MECHANISMS
THAT DOESN'T REQUIRE SO MUCH
HARD WORK SO WE CAN PROVIDE TO
THE COMMUNITY THE RESOURCES THEY
NEED WHILE THEY CONTRIBUTE TO
THE RESEARCH THAT IS SO
IMPORTANT FOR US TO MOVE SCIENCE
FORWARD.
AND FURTHER, I THINK WE SHOULD
ALSO INVEST IN EMPLOYEEING
PEOPLE FROM THE COMMUNITY TO BE
PART OF THE RESEARCH PROJECTS
THEY IMPLEMENT.
THEY HAVE THE LIVED EXPERIENCES
AND WE CAN CONTRIBUTE BY
BUILDING CAPACITY THAT WILL STAY
IN THE COMMUNITY.
>>THANK YOU.
DR. McCOY, WOULD YOU LIKE TO ADD
TO WHAT IS NEEDED FOR COMMUNITY
ENGAGEMENT IN THE IMPLEMENTATION
OF SOME OF THE SCIENCE THAT'S
GENERATED?
>>THANK YOU SO MUCH FOR THE
QUESTION AND THANK YOU TO NIH
AND FOR HAVING ME HERE TODAY.
I'VE AGREED WITH EVERYTHING MY
FELLOW PANELISTS HAVE SAID SO
FAR AND FROM THE IMPLEMENTATION
STANDPOINT, I THINK AN IMPORTANT
CONSIDERATION IS THAT SOMETIMES
COMMUNITY ENGAGEMENT CAN BE
SUPERFICIAL.
I THINK IT'S NOT ALWAYS THE CASE
THAT RESEARCHERS HAVE MEANINGFUL
ENGAGEMENT OF COMMUNITY MEMBERS
IN THE RESEARCH OR EVEN HAVE
ROBUST DISSEMINATION PLANS THAT
CAN RESULT IN MEANINGFUL
TRANSLATION OF RESEARCH FINANCE
INTO PROGRAMS AND POLICIES.
AND SO I THINK AN IMPORTANT
FACTOR TO CONSIDER REALLY IS THE
BUDGET LIMITS.
THE CURRENT FUNDING AND OTHER
FUNDERS TO ALLOW FOR MEANINGFUL
ENGAGEMENT OF COMMUNITIES.
I THINK WE'VE BEEN INCREASINGLY
ASKED TO DO MORE AND MORE AND I
THINK WE WOULD HAVE A BETTER
OPPORTUNITY TO ENGAGE
COMMUNITIES AND SPECIFICALLY TO
PAY PEOPLE FOR THEIR EXPERTISE
AND LIVED EXPERIENCE FOR THEIR
KNOWLEDGE ABOUT THEIR
COMMUNITIES.
IF WE HAD FUNDING TO DO THAT.
I THINK THAT'S AN IMPORTANT
CONSIDERATION FOR US MOVING
FORWARD AND FOR PEOPLE LIKE ME
MID CAREER AND SENIOR CAREER WE
NEED TO DO BETTER ON TO THE
MENTORSHIP SIDE.
THERE'S WIDE AGREEMENT WHEN
PEOPLE FROM THE COMMUNITIES MOST
AFFECTED BY HIV BOTH
DOMESTICALLY AND GLOBALLY THE
RESEARCH IS BETTER AND CAN OFTEN
BE MORE IMPACTFUL ONCE
IMPLEMENTED IN THOSE
COMMUNITIES.
>>THANK YOU, DR. McCOY.
LET'S MOVE TO ANOTHER AREA AND
THAT IS THE GROWING NUMBER OF
PEOPLE LIVING IN HIV WHO ARE
THANKFULLY AGING AND NOW OVER
AGE 50.
I THINK IT BEGS THE QUESTION OF
WHAT ARE THE CHALLENGES THAT ARE
THERE?
WHAT NEEDS TO BE DEVELOPED FOR
BETTER TREATMENTS THAT REALLY
ADDRESS COMORBIDITIES ACROSS THE
LIFE SPAN?
SO DR. APPLEBAUM, WHAT ARE THE
MAJOR RESEARCH CHALLENGES YOU
SEE THAT ARE ASSOCIATED WITH
AGING AND HIV AND PERHAPS
RELATED TO THAT, WHAT ARE YOUR
SUGGESTIONS FOR POTENTIAL
INNOVATIONS OR ADVANCES IN THAT
AREA?
>>THANK YOU, THAT'S AN
EXCELLENT TOPIC, DR. HODDER.
LIKE THE OTHERS I APPRECIATE
BEING ABLE TO JOIN THIS
DISTINGUISHED PANEL AND
SPEAKERS.
AS YOU ALLUDED TO IN YOUR
OPENING REMARKS, WE'RE FACING
WHAT SOME PEOPLE CALL A SILVER
TSUNAMI THE WAVE OF THE MAJORITY
OF OUR PATIENTS LIVING WITH HIV
IS NOW OVER 50.
AND IF YOU THINK BY THE END OF
THE DECADE THEY'LL BE OVER 60
AND THAT'S A TRIBUTE TO WHAT
WE'VE BEEN ABLE TO DO AS FAR AS
TREATMENTS AND NEW INFECTIONS.
SO FROM THE CLINICAL SIDE WHICH
IS WHERE I WEAR MY HAT, I THINK
WE NEED TO LOOK AT A NUMBER OF
THINGS.
ONE IS A WORKFORCE ISSUE BECAUSE
MANY OF US THE FIRST GENERATION
OF PROVIDING CARE FOR HIV ARE
APPROACHING RETIREMENT AND A
DON'T SEE A LOT OF CLINICAL
FOLKS COMING BEHIND US.
AS THE WAVE OF OLDER PATIENTS
LIVING WITH HIV PROGRESS,
THEY'RE GOING TO NEED MORE AND
MORE CLINICAL EXPERTISE.
THIS IS AN AREA WHERE INFECTIOUS
DISEASE, PRIMARY CARE AND
GERIATRICS INTERSECT.
I THINK AN AREA OF RESEARCH
NEEDS TO BE HOW DO WE DEAL WITH
THIS.
HOW DO WE TRAIN AND DEPLOY THE
NEXT GENERATION OF PROVIDERS FOR
OUR COMMUNITY LIVING WITH HIV.
SO I THINK THAT'S THE PRIMARY
THING.
I THINK THE OTHER PIECE I WOULD
DO RESEARCH ON IS BECAUSE OF ALL
THE COMORBIDITIES OUR OLDER
POPULATION LIVING WITH HIV HAS,
HOW DO WE PRIORITIZE THE CARE
AND WHAT THE TOOLS THAT WE NEED
TO MAKE CARE FOR THEM
STANDARDIZED AND EFFICIENT TO
ALLOW THEM TO LIVE INTO THEIR
70s, 80s AND 90s?
THAT'S AN OVERVIEW.
I CAN GO ON FOR A LONG TIME
TALKING ABOUT SOME OF THE OTHER
AREAS OF RESEARCH BECAUSE WE ALL
KNOW THERE HAS NOT BEEN A TON OF
RESEARCH DONE ON OLDER PATIENTS
LIVING WITH HIV.
FOR MANY YEARS THEY WERE
EXCLUDED FROM CLINICAL TRIALS
AND PARTICULARLY IF THEY HAD
COMORBIDITIES.
WE NEED TO LOOK AT HOW WE
INCLUDE THEM IN CLINICAL TRIALS.
THAT'S FROM THE CLINICAL
PERSPECTIVE AND I HAVEN'T
TOUCHED ON SUBSTANCE ABUSE AND
ISSUES OF LONELINESS THAT ARE
PERVASIVE IN THIS POPULATION.
I'LL END THERE.
>>THAT'S A TANTALIZING END
BECAUSE IT SOUNDS LIKE ANOTHER
PROGRAM.
I'D LIKE TO GO BACK TO
DR. McCOY.
WHAT IS IMPLEMENTATION SCIENCE
HAVE TO OFFER THE AREA OF AGING
AND HIV RESEARCH?
>>IMPLEMENTATION SCIENCE IS THE
STUDY OF PROGRAMS AND POLICIES.
IMPLEMENTATION SCIENCE HELPS US
FIGURE OUT HOW TO GET VACCINES
INTO ARMS OR GET PREP TO THOSE
WHO WOULD BENEFIT.
IT'S ALWAYS TO CENTER THE
COMMUNITIES WE ARE HOPING TO
SERVE.
THAT'S THE CENTRAL TENET OF THE
KIND OF WORK IMPLEMENTATION
SCIENCE WANTS TO DO.
WE ESSENTIALLY WANT TO CENTER
THOSE INDIVIDUALS.
SO I THINK WITH ISSUES AROUND
AGING AND HIV WE TAKE THE SAME
PERSPECTIVE AS TO WORK CLOSELY
WITH PEOPLE AT DIFFERENT STAGES
OF THE LIFE COURSE AND LIFE
PHASES AND UNDERSTAND WHAT ARE
THEIR NEEDS AND PREFERENCES AND
THE THINGS THAT ARE IMPORTANT TO
THEM AT DIFFERENT STAGES OF LIFE
AND HOW CAN WE MAKE SURE THAT
LIVING WITH HIV CAN BE
SUCCESSFUL WITH THOSE DIFFERENT
MOTIVATIONS AND PREFERENCES
ALONG THE LIFE COURSE.
>>THANK YOU SO MUCH.
AND BACK TO DR. BROWN.
ONE OF YOUR AREAS OF EXPERTISE
IS CNS INFLAMMATION AND AGING
POPULATIONS AND NOT JUST HIV BUT
AGING POPULATIONS IN GENERAL.
THERE'S ALL THESE CONCERNS WITH
INCREASING INCIDENTS OF
COGNITIVE ISSUES.
WHAT DO WE NEED TO DO IN THE
AGING RESEARCH AGENDA TO ADDRESS
COGNITIVE FUNCTION IN THAT AREA?
>>THANK YOU.
CENTRAL TO THAT IS THE MYELOID
CELLS PART OF THE CENTRAL
NERVOUS SYSTEM THAT ARE
INTIMATELY INVOLVED IN THE
NEURAL PATHOGENESIS OF THE
DISEASE.
AND WE'VE HAD BARRIERS TO
STUDYING THE HUMAN NERVOUS
SYSTEM BECAUSE THERE'S
LIMITATIONS AND RIGHTLY SO OF
WORKING WITH HUMANS BUT THERE'S
BEEN ADVANCES IN RODENT MODELS
WHERE WE CAN NOW BETTER
UNDERSTAND THE ROLE AND FUNCTION
OF THE MICROGLIA IN PARTICULAR.
IT SERVES AS A HOST FOR THE
VIRUS AND PROPAGATING SOME OF
THE ONGOING NEGATIVE IMPACTS
THAT ARE VISIBLE UPON NEURAL
PSYCHOLOGICALING AND THE NEURAL
PSYCHIATRIC COMORBIDITIES THOSE
AGING WITH HIV ARE EXPERIENCE.
CONTINUED EFFORT ON THAT LINE
ARE VERY IMPORTANT.
AND I JUST WANTED TO -- I DON'T
KNOW IF THIS IS THE TIME BUT I
WANTED TO STEP BACK AND COMMENT
ON THE COMMUNITY ENGAGEMENT.
FOR ME, IT'S -- I ALWAYS LEARN
WHEN I'M PART OF THESE PANELS
AND ONE OF THE LIMITATIONS IS US
AS SCIENTISTS HAVING THE
LANGUAGE TO SPEAK WITH FOLKS WHO
ARE PART OF OUR COMMUNITY AND SO
LIVED EXPERIENCES AND
IMPLEMENTATION SCIENCE.
WE HAVE AS PART OF OUR ONE OF
OUR LARGER MULTI-CORE GRANTS
HAVE INITIATIVE WHERE WE'RE
GOING TO TRAIN OUR SCIENTISTS TO
TALK TO BE ABLE TO SPEAK TO
COMMUNITY TO OUR SURROUNDING
COMMUNITY ABOUT THE WORK WE ARE
DOING.
THANK YOU.
>>THANK YOU FOR THAT.
THAT IS SO IMPORTANT AND MANY
TIMES NOT PRESENT SO THANK YOU.
LET'S SEGUE TO THE AREAS OF
HEALTH DISPARITIES A BARRIER IN
THE HIV RESPONSE.
COVID-19 AND THE MONKEY POX
EPIDEMIC HIGHLIGHTED THE
CRITICAL HEALTH PROBLEM.
I WONDER IF YOU CAN COMMENT AS
RESEARCH ENABLES PREVENTING AND
DIAGNOSING AND TREATING HIV, HOW
CAN WE ENSURE THE TOOLS AND
RESOURCES END UP IN THE HANDS OF
THE COMMUNITIES THAT NEED THEM
THE MOST?
>>THAT'S AN IMPORTANT QUESTION
AND LAYERED ONE.
ONE IS RECOGNIZING WHEN WE TALK
ABOUT COMMUNICATING THOSE MOST
IMPACTED BY HIV THEY'RE NOT ALL
THE SAME.
WE WERE TALKING ABOUT WHAT WE
NEED TO REACH BLACK MEN AND
THEY'RE NOT ALL THE SAME AND
GOING BACK TO THE QUESTION ABOUT
AGING AS WE DO WITH SINGLE MEN
LIVING WITH HIV AND AGING OVER
THE AGE OF 50 THEY TALK ABOUT
THERE'S BEEN NO EXAMPLES OF
ELDERSHIP IN THAT COMMUNITY.
WE TALK ABOUT THE IDEA OF AGING
WITH HIV AND WHAT THEIR
INVOLVEMENT COULD OR SHOULD BE
WHEN IT COMES TO THE AS IT
PERTAINS TO INTERSECTING ISSUES
AND WE TALK ABOUT HEALTH
DISPARITIES.
RECOGNIZING SOME OF THE SOCIAL,
CULTURAL INFLUENCES WHERE THERE
HAVE NOT BEEN EXAMPLES AND HOW
THAT MIGHT IMPACT OUR ABILITY TO
CONDUCT AND ENGAGE EFFECTIVELY
IN RESEARCH.
I'M CURRENTLY SITTING IN
MONTGOMERY, ALABAMA AS WORLD
AIDS DAY COINCIDES WITH ROSA
PARKS DAY ON THE DAY SHE DID NOT
GIVE UP HER SEAT ON THE BUS IN
1955 AND HAVING CONVERSATIONS
WITH PEOPLE AROUND THE VARYING
INTERSECTIONS ABOUT THE HISTORY
OF THE CIVIL RIGHTS MOVEMENT AND
THE CHALLENGES AROUND ACCESS TO
HEALTH CARE THAT EXIST IN
ALABAMA AND THE SOUTH AND
THROUGHOUT THE NATION.
SO MUCH OF OUR CONVERSATION HAS
TO NOT BE THE SILO OF HIV, BUT
UNDERSTANDING HIV AND HIV
RESEARCH IN THE CONTEXT OF
BROADER HEALTH CHALLENGES OUR
COMMUNITIES ARE FACING AND THE
NEED TO AND THE OPPORTUNITIES TO
EXIST FOR RESEARCH AND POLICY
AND ADVOCACY TO WORK HAND IN
HAND TO ENSURE WE CAN
EFFECTIVELY ADDRESS THE HEALTH
DISPARITIES IN OUR COMMUNITIES.
>>THANK YOU FOR THAT.
THAT'S VERY IMPORTANT.
DR. RODRIGUEZ-DIAZ, WHAT IS
NEEDED IN VARIOUS COMMUNITIES?
>>I WOULD USE AN EXAMPLE OF THE
DIVERSITY WITHIN THE DIVERSE
COMMUNITIES WE WORK WITH.
AS A LATINO AND PUERTO RICAN I
WORK WITH PUERTO RICAN AND
LATINX COMMUNITY.
WE NEED TO RESEARCH THAT IS
RELEVANT AND SOMETIMES REQUIRES
US TO DO RESEARCH IN SPANISH
BECAUSE IT'S THE PREFERRED
LANGUAGE OF OUR PARTICIPANTS.
AND IT IS IMPORTANT THAT
SCIENTISTS AND COMMUNITY
PARTNERS AND ADVOCATES
UNDERSTAND THAT HAVING A
RESEARCH BEING IMPLEMENTS IN
SPANISH IS NOT ABOUT TRANSLATING
THE MATERIALS.
IT'S TO MAKE MATERIALS
CULTURALLY APPROPRIATE TO HAVE
THE COMMUNITY PARTICIPATING IN
CREATING THE MATERIALS.
EVEN THE STRATEGIES THAT WE USE.
OUR SCIENTIFIC AIMS AND GOALS
AND MANTRAS DON'T NEED TO BE
COMPROMISED ON IN ANY WAY.
ON THE CONTRARY, ENGAGING THE
COMMUNITY MAKES OUR WORK EVEN
BETTER.
WHEN WE ENGAGE THE COMMUNITY WE
NEED STEPS TO ENSURE WE'RE DOING
THE RIGHT THING.
FOR THAT WE NEED SUPPORT FROM
THE SYSTEM THAT PROVIDED THE
DIFFERENT RESOURCE ARE NEEDED.
AND I ECHO THE CALL TO MAKE SURE
THAT IN THIS CASE I'M USING AN
EXAMPLE OF THE LATINO COMMUNITY
BUT IT'S RELEVANT ACROSS
DIFFERENT GROUPS
DISPROPORTIONATELY AFFECTED BY
HIV.
>>MS. WARD I SEE YOU SHAKING
YOUR HEAD.
WOULD YOU LIKE TO ADD A COMMENT?
>>THAT'S AN AMEN NOD.
HE'S SPOT ON.
AS IT'S A CHALLENGE WE FACE IN
RESEARCH AND COMMUNITY WORK IN
GENERAL IS NOT THINK BEING
GOOGLE TRANSLATE IS EFFECTIVE TO
ENGAGE A COMMUNITY AND
MEANINGFULLY ENGAGE THEM.
I APPRECIATE THAT.
>>THANK YOU.
DR. McCOY, WHAT ARE YOUR
THOUGHTS?
>>THERE'S SO MANY LAYERS TO THE
ISSUE OF HOW DO WE GET
INNOVATIVE PRODUCTS AND SERVICE
TO COMMUNITIES THAT WILL
BENEFIT.
WE'VE OBVIOUSLY MADE PROGRESS IN
THE AREA IN THE LAST 40 YEARS
BUT 1 1/2 MILLION PEOPLE
ACQUIRED HIV LAST YEAR SO
THERE'S MORE WORK TO DO.
AND TO ADD WHAT MY COLLEAGUES
HAVE ALREADY SAID, FROM A SUPPLY
CHAIN PERSPECTIVE WE NEED TO BE
MORE PROACTIVE AND ANTICIPATE
BOTTLENECKS BEFORE SERVICES ARE
RELEASED.
WHAT WE EXPERIENCED WITH GETTING
COVID-19 VACCINES TO UNDER
SERVED COMMUNITIES IN THE
U.S. AND LOW AND MIDDLE INCOME
COUNTRIES WILL BE THE SAME WHEN
WE HAVE A HIV VACCINE.
THE MORE WE CAN PRE-NEGOTIATE
AND ESTABLISH MECHANISMS FOR
PRICING AND PROCUREMENT BEFORE
PRODUCTS ARE AVAILABLE, WILL
HELP ENSURE THE DELIVERY OF THE
NEW INNOVATIONS TO COMMUNITIES
WILL BE LESS INTERRUPTED.
I ALSO THINK WHENEVER POSSIBLE,
POLICY MAKERS ARE INVOLVED IN
THE PROCESS.
ONE IMPLICATION IS WHEN WE
ENGAGE THEM IN THE RESEARCH IT
HELPS TO ENSURE THE RESULTS ARE
PRESENTED IN A WAY THEY CAN
UNDERSTAND AND HELP TO EMPOWER
POLICY MAKERS TO ASSESS THE
VALUE OF THEM FOR PEOPLE IN
THEIR CONSTITUENCY AND WHEN
POLICYMAKERS ARE INVOLVED IN THE
DESIGN AND RESOURCES IT CAN
INCLUDE THE LIKELIHOOD THE
RESOURCES WILL HAVE IMPACT IN
THE POPULATION BECAUSE IT CAN
HELP TO BETTER CENTER THE
COMMUNITIES AND SUBGROUPS WE
BENEFIT.
YOU CAN SEE THE THEME IN WORKING
WITH AND FOR COMMUNITIES MOST IN
NEED.
AND I MENTIONED IMPLEMENTATION
SCIENCE.
IT'S KEY TO REMEMBER THE SUCCESS
OF AN EVIDENCE-BASED PREVENTION
TOOL CAN BE ACCELERATED OR
HINDERED BY THE IMPLEMENTATION
STRATEGY.
OUR TEAM IS USING PUBLIC-PRIVATE
PARTNERSHIPS TO REACH PEOPLE WHO
MAY NOT OTHERWISE WANT TO GO TO
A STANDARD BRICK AND MORTAR
HEALTH FACILITY AND BE DETERRED
BUT WE NEED MORE RESEARCH AND
TRAINING AND IMPLEMENTATION
SCIENCE.
LASTLY I WANTED TO MENTION DATA.
FROM A DATA PERSPECTIVE WE NEED
TO COLLECT AND ANALYZE DATA
QUICKLY SO SYSTEMS AREN'T
GETTING PRODUCTS AND SERVICES TO
THE COMMUNITIES MOST IN NEED CAN
QUICKLY PIVOT AND USE DATA TO
EVALUATE GOOD IDEAS.
UNDERLYING ALL THE STRATEGIES
THE MORE WE CAN HAVE HIV
RESEARCHERS, NIH-INVESTIGATOR
MOST AFFECTED IN THESE
COMMUNITIES IT WILL ALL BE
ENHANCED.
>>IN WEST VIRGINIA WE HAVE TWO
ONGOING HIV EPIDEMICS IN A
CLIMATE ARE RECENT LEGISLATURE
MADE IT MORE DIFFICULT AND
STEMMING AN HIV OUTBREAK IN
POPULATIONS OF FOLKS WHO USE
INTRAVENOUS DRUGS YET THERE'S
ZERO NIH, HIV PREVENTION OR
TREATMENT TRIALS TO MY KNOWLEDGE
IN WEST VIRGINIA.
WE NEED TO LOOK AT TRIALS FOR
HIV PREVENTION FROM COMMUNITIES
WITH DEEP INPUT FROM THOSE
COMMUNITIES ON WHAT WILL WORK.
I APPRECIATE YOUR COMMENTS.
DR. APPLEBAUM, WHAT IS YOUR TAKE
ON WHAT'S NEEDED FOR HEALTH
DISPARITIES?
YOU'VE BEEN IN THE BUSINESS AS
LONG AS I HAVE.
WHAT DO WE NEED DO?
-- TO DO?
>>LISTENING TO THE COMMENTS
MADE, A COUPLE THEMES.
ONE, WE NEED TO BE INTENTIONAL
ABOUT THE COMMUNITIES WE'RE
TRYING TO DEAL WITH AND REALIZE
COMMUNITY IN ONE PLACE NOT THE
SAME AS THE COMMUNITY IN ANOTHER
PLACE.
WE NEED TO BE NIMBLE.
THAT'S ONE OF THE THINGS ANOTHER
THEME I'M HEARING.
WE NEED TO BE QUICK ON THE DRAW
AROUND SAY AN EPIDEMIC OF HIV
RELATED TO OPIOID USE.
BUT WE ALSO IN ADDITION TO BEING
IMBALL WE NEED TO UNDERSTAND
SOMETIMES WE NEED TO SHIFT
QUICKLY AND DO ANALYSIS OF THE
DATA QUICKLY AND MAYBE CHANGE
OUR STRATEGY.
ALMOST LIKE A QUICK QUALITY
IMPROVEMENT CYCLE AND SO THAT I
THINK IS SOMETHING THAT WE COULD
STRESS THROUGH NIH AND AS THEY
PLAN THE RESEARCH IN THE FUTURE.
>>THANK YOU FOR THAT.
THAT'S VERY INSIGHTFUL.
LEA LET'S MOVE TO AN AREA OF
BASIC RESEARCH.
WHICH BASIC SCIENCE RESEARCH WAS
SO FUNDAMENTAL THROUGHOUT THE
HIV EPIDEMIC UNDERSTANDING THE
VIRUS WHAT IT WAS DOING, TARGETS
FOR DRUG DEVELOPMENT FOR
TREATMENT FOR PREVENTION.
YOU
>>DR. BROWN, THIS IS TOUGH
QUESTION SO I APOLOGIZE AND WHAT
ARE THE BASIC LINES OF RESEARCH
THAT WOULD BE MOST IMPACTFUL
OVER NEXT FIVE YEARS?
>>THANK YOU.
ONE I THINK IS CRUCIAL IS OUR
UNDERSTANDING OF HOW THE
INFLAMMATORY RESPONSE IS
REGULATED.
WE'VE TALKED ABOUT AGING WITH
HIV.
OTHER COMORBIDITIES, SUBSTANCE
ABUSE.
ALL THESE FACTORS CAN BE
MODULATED BY INFLAMMATION
EXACERBATED BY INFLAMMATION.
NOW, WE NEED A MINIMUM LEVEL OF
INFLAMMATION TO MOBILIZE THE
IMMUNE RESPONSE TO FIGHT AGAINST
HIV AND OTHER PATHOGENS BUT WHEN
IT IS CHRONIC AND ONGOING, THAT
IS WHEN IT LEADS TO THESE
SPECIFIC ORGAN DAMAGE.
IT RELATES TO ALL THE
COMORBIDITIES THAT WE SEE IN HIV
SO HAVING -- GAINING A GREATER
UNDERSTANDING, WE KNOW A LOT OF
HOW INFLAMMATION CAN BE PRIMED
AND PROPAGATED BUT REALLY
GETTING MORE DETAIL IN THE
MOLECULAR MECHANISMS AND
PATHWAYS THAT CONTROL THE
INFLAMMATION TO TURN IT OFF AND
ON COULD REALLY BE
TRANSFORMATIVE.
NOT JUST FOR HIV BUT FOR SO MANY
OTHER DISORDERS.
>>CERTAINLY I THINK THE COVID
PANDEMIC BROUGHT THAT HOME AND
ONE OF THE THEMES HAS BEEN WHAT
HIV AND ALL THE ADVANCES IN HIV
BROUGHT TO ADDRESSING THE COVID
PANDEMIC BUT I THINK CERTAINLY
INFLAMMATION ACUTELY AND
CHRONICALLY IN COVID-19 IS
REALLY AT THE FORE.
I THINK WHAT WE LEARNED CROSS
THESE AREAS WILL BE VERY
HELPFUL.
DR. APPLEBAUM, WHAT WOULD YOU
LIKE TO SEE AND WHAT QUESTION IS
MORE IMPACTFUL?
>>CLEARLY WE GET PEOPLE LIVING
WITH HIV UNDETECTABLE BUT STILL
HAVE ONGOING INFLAMMATION GOING
ON.
GETTING CONTROL OF THAT,
FIGURING OUT THE PROCESSES AND
WHAT WE CAN DO TO MITIGATE THAT
MAY HELP TO ANSWER SOME OF THE
RESEARCH QUESTIONS WE HAVE.
I MEAN THERE'S ONE QUESTION I
DON'T THINK THAT'S BEEN
ADEQUATELY ANSWERED WHICH DOES
HIV AGE SOMEONE EARLIER?
ARE THESE MULTI-MORBIDITY WE SEE
RELATED TO THE ONGOING LOW-GRADE
INFLAMMATION?
I THINK IT'S A GREAT QUESTION
AND AS A GERIATRICIAN, HOW DO WE
INTERVENE IN SOMEONE DEVELOPING
FRAILTY.
WE DON'T HAVE A LOT OF GOOD
INTERVENTIONS NOW BUT THE
INCIDENTS OF FRAILTY IN OUR
POPULATION OF OLDER PATIENTS
LIVING WITH HIV IS HUGE.
AND THAT'S A RISK FACTOR FOR
LOTS OF THINGS INCLUDING FALLS,
DEATH AND INSTITUTIONALIZATION.
IF WE CAN DO MORE BASIC RESEARCH
ON FRAILTY I THINK THAT WOULD BE
HELPFUL.
>>THANK YOU, DR. APPLEBAUM.
DR. McCOY TURNING THE QUESTION
TO IMPLEMENTATION SCIENCE, WHAT
DO YOU THINK WOULD BE THE
RESEARCH QUESTION OR QUESTIONS
AND IMPLEMENTATION SCIENCE THAT
WOULD BE MOST IMPACTFUL IF WE
CAN ANSWER THEM OVER THE NEXT
FIVE YEARS?
>>I THINK AN AREA ON THE
HORIZON FOR US AND A REAL
PRIORITY AREA IS TO THINK ABOUT
HOW CAN WE USE IMPLEMENTATION
SCIENCE TO REACH SUBGROUPS WHO
MIGHT BE LEFT OUT OF TRADITIONAL
DELIVERY CHANNELS.
SO I THINK WE'VE DONE A GREAT
JOB INCREASING PEOPLE'S ACCESS
AND I THINK SPECIFICALLY FROM
THE PERSPECTIVE OF GLOBAL HEALTH
AND LOW AND MIDDLE INCOME
COUNTRIES YOU CAN GO INTO
PHARMACIES NOWADAYS AND SEE
THINGS LIKE HIV TEST KITS ON
PHARMACY SHELVES AND SEE
DISTRIBUTION OF MEDICATIONS AT
GOVERNMENT CLINICS AND HAVE LED
TO THE SUCCESSES WE TALKED ABOUT
AT THE TOP OF THE SESSION TODAY.
AT THE STATEMENT TIME WE HAVE
VULNERABLE GROUPS LEFT OUT OF
SOME OF THOSE CHANNELS.
THESE ARE INDIVIDUALS WHO ARE
MAYBE ENGAGED IN SEX WORK OR
GIRLS AND YOUNG WOMEN OR MEMBERS
OF THE LGBTQ COMMUNITY
PARTICULARLY IN AREAS WHERE THAT
COULD BE A DANGEROUS LIFESTYLE.
I THINK THERE ARE SUBGROUPS THAT
WE NEED TO DO BETTER REACHING
AND IMPLEMENTATION SCIENCE CAN
HELP US DO THAT AND CAN UNCOVER
DELIVERY MECHANISMS, DELIVERY OF
HIV PREVENTION AND CARE OUTSIDE
OF TRADITIONAL HEALTH CARE
DELIVERY MECHANISMS LIKE THROUGH
BRICK AND MORTAR HEALTH CLINICS.
REACHING PEOPLE WHERE THEY ARE,
PHYSICALLY AND BEHAVIORALLY.
AND SO I THINK THAT'S AN
IMPORTANT ISSUE ON THE HORIZON
FOR THOSE OF US WHO DO THIS KIND
OF IMPLEMENTATION BEHAVIORAL
WORK.
>>THANK YOU.
THANK YOU VERY MUCH.
BEFORE WE MOVE TO THE QUESTIONS
FROM OUR VIEWERS, MS. WARD, WHAT
IS YOUR TAKE?
WHAT ARE THE IMPORTANT RESEARCH
QUESTIONS THAT REALLY NEED TO BE
ANSWERED IN THE NEXT FIVE YEARS?
>>I DON'T HAVE THE SCIENTIFIC
PROGRAM OF SOME OF MY PEERS ON
THE PANEL IN THAT REGARD BUT I
THINK ABOUT THE QUESTIONS I HEAR
COME FROM COMMUNITY AND WHAT
THEY WOULD LIKE TO UNDERSTAND
BETTER AND ONE OF THOSE WOULD BE
AS IT RELATES TO CISGENDER WOMEN
AND THE IMPACT OF THEIR HIV
DIAGNOSIS IN REPRODUCTIVE HEALTH
AND THINGS THEY NEED TO KNOW AND
INFORMATION TO REMAIN THE MOST
HEALTHY AND IN PREPARATION IF
IT'S THEIR DESIRE FOR PEOPLE WHO
MAY WANT TO BECOME PREGNANT.
REALLY TRULY UNDERSTANDING HOW
HIV IMPACT THAT.
AND ALSO FOR THOSE WHO ARE DOING
WORK AROUND FOLKS OF TRANS
EXPERIENCE NEEDING AND WANTING
TO SEE THEMSELVES IN THE
RESEARCH.
SO HOW DO WE DO A BETTER JOB OF
MAKING SURE THOSE OF TRANSGENDER
EXPERIENCE SEE THEMSELVES IN THE
RESEARCH AND ONE OF THE BASIC
THINGS IS ARE DATA TELLING THE
STORY AND CAPTURING THE
EXPERIENCE OF THOSE WHO IDENTIFY
AS TRANSGENDER WHO OFTEN GET
LINKED INTO OTHER CATEGORIES
WHEN WE TALK ABOUT HIV
DIAGNOSIS.
THOSE WILL BE TREMENDOUSLY
HELPFUL WHEN YOU TALK ABOUT WORK
AND PREVENTION AND LINKING FOLKS
TO CARE AND COMMUNITIES AND
SEEING THEMSELVES IN THE
RESEARCH.
>>THANK YOU FOR THAT.
THAT IS REALLY USEFUL TO PUT THE
IMPORTANT RESEARCH QUESTIONS IN
CONTEXT.
WHAT WE'RE GOING TO DO NOW IS
TAKE QUESTIONS FROM OUR VIEWERS
THAT I'M SEEING HERE ON CHAT.
I'LL SORT OF READ THE QUESTION
AND IF ANY OF THE PANELISTS
PARTICULARLY WANT TO ANSWER,
SORT OF RAISE YOUR HAND
OTHERWISE I'LL JUST DRAFT
SOMEBODY.
THE FIRST QUESTION IS PEOPLE
WITH DISABILITIES OFTEN LACK
ACCESS TO HEALTH CARE BOTH
PHYSICALLY AND DIGITALLY AS WELL
AS PROGRAM ACTIVITIES.
THIS LEADS TO HEALTH CARE
DISPARITIES AND HEALTH CARE
OUTCOMES AS SEVERELY -- THIS
LEADS TO HEALTH CARE DISPARITIES
AND HEALTH CARE OUTCOMES.
IF WE CAN SCROLL UP AS ANY
MINORITIZED COMMUNITY.
WHAT ARE YOUR THOUGHTS ON WHY
PEOPLE LIVING WITH DISABILITIES
ARE EXCLUDED FROM DATA
COLLECTION, TARGETED OUTREACH
AND REALLY ENGAGEMENT?
WHAT MESSAGES DO YOU HAVE AS FAR
AS SOLUTIONS, POSSIBLE SOLUTIONS
TO THIS INEQUALITY.
I DON'T KNOW -- I DON'T SEE
ANYBODY'S HAND BUT MS. WARD DO
YOU WANT TO TAKE THAT ONE ON?
I KNOW THERE'S A LOT OF
QUESTIONS IN THERE.
>>THERE ARE A LOT OF QUESTIONS
IN THERE.
I THINK MANY OF US IN THIS WORK
KNOW WE CAN BE UNINTENTIONALLY
ABLISTS IN THE WAY WE DO OUR
WORK AND BASIC THINGS IN HAVING
INTERPRETATION, WHETHER IT'S
SIGN LANGUAGE OR OTHER RESOURCES
IN WRITING, DO WE THINK ABOUT
BRAILLE?
THE RANGE OF WAYS WE COULD BE
MORE INCLUSIVE IN OUR PLANNING
AND WE TOUCHED ON MENTAL HEALTH.
WHEN WE TALK ABOUT FOLKS
DIFFERENTLY ABLED WE MAY
IDENTIFY AS BEING DISABLED BUT
IT CAN MEAN DIFFERENT THINGS.
HOW WE NEED TO THINK MORE
BROADLY IN THE CONTEXT OF OUR
WORK AND MAKING SURE IT IS FULLY
ACCESS AS MUCH AS POSSIBLE.
THERE'S ALSO OPPORTUNITIES TO
BUILD PARTNERSHIPS.
I THINK THAT WOULD HELP US TO DO
THAT.
THIS SPEAKS TO THE FILE JO --
SILOING OF OUR WORK IN HIV AND
WORKING IN COLLABORATION WITH
ORGANIZATIONS THAT HELD THE
EXPERTISE AND CAN HELP US DO
THAT BETTER.
I GREATLY APPRECIATE THAT
QUESTION.
IT'S AN IMPORTANT ONE.
>>DR. RODRIGUEZ-DIAZ, WOULD I
LIKE TO ADD TO THAT?
>>SURE.
I WILL ADD THAT WE CAN INTEGRATE
DIFFERENT COMMUNITIES WITH THE
DISABILITIES TO THE PLANNING IN
THE WORK WE DO AS RESEARCHERS.
AND ALSO PROVIDE TRAINING.
SO WE WERE TALKING EARLIER IN
THE CONVERSATION ABOUT
ADDRESSING THE PART YES IN
TRAINING AND THE NEW GENERATION.
THE NEWER GENERATION HAS
DIFFERENT ABILITIES AND
DISABILITIES WHEN WE THINK ABOUT
HOW THE PROGRAMS LOOK LIKE AND
WE NEED TO CLOSE THE SILOS WE'VE
HAD HISTORICALLY KEPT IN THE
RESPONSE TO HIV.
>>DR. BROWN AND DR. McCOY I'LL
GET TO YOU.
>>I'LL QUICKLY ADD THAT FOR OUR
UNDERGRADUATE TRAINING, ONE OF
OUR UNDERGRADUATE TRAINING
PROGRAMS WE HAVE A PARTNERSHIP
WITH THE FACULTY MEMBER WHO
THEMSELVES IS DEAF, HEARD OF
HEARING.
WE HAVE TRAINEES.
WE ATTRACT TRAINEES DEAF, HARD
OF HEARING AND A LOT OF THE
RESOURCES OF THE COMMUNITY TENDS
TO GO TO ONE ORGANIZATION IN
PARTICULAR.
AND SO MAKING SURE THAT
RESOURCES FOR THE DIFFERENTLY
ABLED ARE MORE PROBABLY
AVAILABLE IS CRITICAL.
>>THANK YOU.
DR. McCOY.
>>I JUST WANTED TO ADD I THINK
WE ALL PROBABLY FEEL PRETTY
PASSIONATE ABOUT THE PROJECT.
I MET A GENTLEMAN STRUGGLING
WITH ART ADHERENCE.
WHEN WE MET IN PERSON HE WAS
HEARING IMPAIRED AND COULD NOT
COMMUNICATE WITH HIS PROVIDER TO
UNDERSTAND HOW TO BE ADHERENT TO
ART AND US BEING NOT INCLUSIVE
HAS REAL IMPLICATIONS.
WE KNOW INDIVIDUALS BENEFIT AND
THERE'S SECONDARY TRANSMISSION
IN COMMUNITIES AND THIS ALIGNS
WITH SOMETHING I SAID EARLIER
THAT NOW WE CAN START TO THINK
DEEPLY ABOUT MEETING THE NEEDS
OF SUBGROUPS.
I THINK THIS IS REALLY WHERE
THAT LIES.
WE'VE NOW SOLVED MANY CHALLENGES
IN THE LAST 40 YEARS AND CAN
START TO DO BETTER WHERE WE HAVE
FAILED MEETING THE NEEDS FOR
PEOPLE WITH DISABILITIES.
>>THANK YOU.
THIS NEXT QUESTION I'M GOING ASK
EVERYBODY FOR THEIR TAKE AND I'M
ANTICIPATING OUR PANELISTS MAY
IN THE AGREE.
DR. APPLEBAUM I'LL START WITH
YOU.
THE QUESTION IS WE HEARD ENDING
THE HIV PANDEMIC REQUIRES
ACCELERATED PREVENTION,
TREATMENT AND CURE RESEARCH AND
PROGRAMMING.
AND GIVEN WE ARE IN A CONTINUING
RESOLUTION AND WE DON'T YET KNOW
WHERE THE HIV RESEARCH BUDGET
WILL INCREASE OR NOT.
WHAT ARE YOUR THOUGHTS ON THE
HIGHEST PRIORITY RESEARCH
INVESTMENTS UNDER THESE AREAS?
THAT'S PREVENTION, TREATMENT AND
CURE.
WE'LL START WITH DR. APPLEBAUM
AND GO DOWN THE PANEL.
>>I THINK PREVENTION IS WHERE
I'D PUT THE MONEY.
WE'VE NOT DONE A GREAT JOB
ROLLING OUT THE PREP.
THERE'S DISPARITIES.
GENDER, RACIAL AND THERE'S AGE
DISPARITIES.
THE OLDER POPULATION IS -- JUST
MY BAILIWICK, LESS LIKELY TO GET
PREP BECAUSE PEOPLE DON'T THINK
OLDER PEOPLE HAVE SEX.
THAT'S WHERE I'D PUT THE MONEY
IS PREVENTION.
IN MY OWN PERSONAL OPINION I
DON'T THINK WE'LL MEET THE
TARGETS THE GOVERNMENT SET OUT
WITHOUT A ROBUST STRATEGY.
>>DR. BROWN.
>>YES.
PREVENTION.
WE KNOW HOW TO PREVENT INFECTION
BUT BEHAVIORAL CHANGE IS SO
DIFFICULT.
THROUGH OUR ATTEMPTS IN THE
RESEARCH TOWARDS CURE LEADS TO
LOTS OF INNOVATION AND AGAIN WE
TALKED ABOUT INTERDISCIPLINARY
IMPACT OF HIV RESEARCH.
THIS ALLOWS OUR FIELD TO BE A
LEADER IN THESE AREAS.
WE NEED TO DO IT ALL BUT I'LL
HAVE TO GO WITH CURE RESEARCH.
>>THANK YOU.
DR. McCOY.
>>IT'S SUCH A HARD QUESTION.
I MIGHT PUSH BACK ON THE PREMISE
AND SAY IN SOME WAYS TREATMENT
IS PREVENTION SO THEY'RE ON THE
SAME CONTINUUM.
I THINK WE SAID FOR 10 YEARS OR
MORE SINCE THE ORIGINAL
TREATMENT IS PREVENTION TRIALS
WE WON'T TREAT OUR WAY OUT OF
THE EPIDEMIC.
PREVENTION IS ESSENTIAL AND HAS
TO BE A MAIN FOCUS NOW AND IN
THE FUTURE.
BUT I THINK IT'S IMPORTANT WE
DON'T TURN OUR BACKS ON PEOPLE
LIVING WITH HIV.
WE HAVE TO CONTINUE TO INVEST IN
PROGRAMS AND SERVICES TO ENSURE
THEIR SUCCESS THAT THEY CAN LIVE
LONG, HEALTHY PRODUCTIVE LIVES.
SUPPORTED BY THE RESEARCH
CONTINUUM.
>>MS. WARD.
>>IS THIS IS A HARD ONE BUT I
AGREE WITH THE ANSWER AROUND
PREVENTION.
YES, TREATMENT IS PREVENTION AND
THINKING ABOUT UNDETECTABLE
EQUALS UNTRANSMITTABLE.
WE KNOW WHAT TOOLS WORK BUT
THERE'S RESEARCH AND WORK THAT
NEEDS TO BE DONE GOING BACK TO
THE OPPORTUNITIES TO MEANINGFUL
ENGAGE COMMUNITY IN RESEARCH,
PREVENTION IS PART OF THAT.
>>DR. RODRIGUEZ-DIAZ.
>>I'M GLAD I'M THE LAST ONE
BECAUSE I HAVE EXTRA TIME.
I'M NOT GOING CHOOSE ONE BECAUSE
I THINK I WOULD LIKE TO APPLY A
HEALTH EQUITY LENS AND MAKE SURE
THAT WE INVEST WHERE WE CAN
ADDRESS THE BEST INEQUITIES IN
TERMS OF OUTCOMES AND GROUPS
AFFECTED BY THE EPIDEMIC.
I THINK CHOOSING ONE WOULD NOT
SOLVE AND WOULD NOT ADDRESS AND
EVEN IF I HAVE TO I WOULD SAY
NO.
WE HAVE LIMITED RESOURCES THAT
DOESN'T MEAN WE HAVE TO HAVE A
LIMITED RESPONSE.
SO I WOULD REDISTRIBUTE THE
RESOURCES BUT WOULD NOT LIMIT
THE RESPONSE.
OF COURSE, I KNOW I'M NOT
ANSWERING THE QUESTION BUT I
THINK IT'S THE MOST HONEST
ANSWER THAT I CAN PROVIDE.
>>IT'S THE QUESTION YOU WANT TO
ANSWER WHICH IS ALWAYS
IMPORTANT.
WE HAVE TWO MINUTES.
WHAT I'D LIKE TO DO IS IT GO
DOWN THE LINE FOR A BRIEF VERY
BRIEF CLOSING COMMENTS.
>>IT'S AMAZING TO REFLECT ON
THE ROLE OF BASIC RESEARCH AND
ALL THE DIFFERENT AREAS OF
RESEARCH REPRESENTED BY THE
PANEL THAT HAS COME TO BEAR ON
THIS EPIDEMIC.
IT'S AN HONOR FOR ME TO BE A
PART OF IT AND TRAINING THE NEXT
GENERATIONS OF RESEARCHERS WHO
WILL LEAD US INTO THE FUTURE
PANDEMICS.
>>THANK YOU.
>>DR. APPLEBAUM.
>>I TOOK CARE OF A PATIENT WITH
HIV EARLY 80s AND WE'VE COME A
LONG WAY AND LISTENING TO MY
OTHER PANELISTS WE STILL HAVE
LOTS OF WORK TO DO.
WE CAN'T GIVE UP.
WE CAN'T SIT BACK.
WE JUST HAVE TO KEEP PUSHING
FORWARD FOR OUR PATIENTS.
>>THANK YOU, DR. McCOY.
>>I WANT TO ECHO MY COLLEAGUE
SAYING I WAS HONORED TO BE PART
OF THE DISCUSSION.
ONE THING I'M STRUCK BY IS THE
DIVERSITY OF PEOPLE WE NEED IN
THE ROOM.
IT'S SUCH A COMPLICATED PROBLEM
FOR 40 YEARS AND THERE'S A BIG
TENT AND FOR YOUNG RESEARCHERS
LOOKING TO GET INVOLVED, THERE'S
A PLACE FOR YOU HERE TOO.
>>MS. WARD.
>>THANK YOU SO MUCH.
AN REFLECTING ON WORLD AIDS DAY
AND IN THE CONVERSATION THE
REMINDER THIS IS GOING TO TAKE
AN ARMY OF ALL OF US WITH
VARYING BACKGROUNDS AND
EXPERTISE AND SCIENTISTS AND
RESEARCHERS OVER THE PAST YEARS
HAVE BEEN WARRIORS IN THE FIGHT
AND WE CAN'T -- NO ROLE AND THE
FIGHT TO END THE EPIDEMIC SHOULD
BE UNDER VALUED AND AN
OPPORTUNITY TO LOOK FOR MORE
COLLABORATIVE EXPERIENCE AND TO
TRULY TRUST ONE ANOTHER IN THE
WORK AND HOLD ONE ANOTHER
ACCOUNTABLE THAT WE MEET THE
NEEDS OF THE COMMUNITIES MOST
IMPACTED.
>>DR. RODRIGUEZ-DIAZ.
>>THIS MORNING WHILE HAVING
COFFEE I WAS THINKING WHAT'S THE
MEANING OF THIS DAY, THIS TIME.
I FELT GRATEFUL FOR THE
OPPORTUNITY I'VE HAD TO WORK
AFTER THE ACCOMPLISHMENTS OF SO
MANY OTHER SCIENTIST AND
ACTIVISTS THAT HAVE ALLOWED US
TO BE HERE TODAY.
ALSO AS A REMINDER OF THE FACT
THAT I DON'T KNOW A WORLD
WITHOUT HIV.
I'M A MILLENNIAL SO I'M MORE
COMMITTED THAN EVER TO END THE
HIV EPIDEMIC BECAUSE I WANT MY
GENERATION AND YOUNGER
GENERATION AND THE GENERATIONS
TO COME TO KNOW THE HISTORY OF
THE HIV, CELEBRATE WHAT WE'VE
DONE AND ALSO KNOW A WORLD
WITHOUT HIV.
>>
I WOULD LIKE TO THANK THE
PANELISTS FOR A VERY DYNAMIC
DISCUSSION. NEXT, WE'LL MOVE ON
TO THE PUBLIC QUESTION AND
ANSWER SESSION. PANELISTS, A
FRIENDLY REMINDER TO UNMUTE
YOURSELF WHEN ANSWERING A
QUESTION. THE FIRST QUESTION
>>THREW THANK YOU FOR
>>THANK YOU FOR THE INSIGHTFUL
CONVERSATION.
IT'S MY PRIVILEGE TO INTRODUCE
DR. TIMOTHY HOLTZ FOR CLOSING
REMARKS AND A TRIBUTE TO THOSE
WHO LOST THEIR LIVES TO HIV AND
INVOLVED IN THE FIGHT TO END THE
HIV PANDEMIC.
DR. HOLTZ IS THE DEPUTY DIRECTOR
OF AIDS RESEARCH AND ASSIST
JACKET SURGEON GENERAL IN THE
PUBLIC HEALTH SERVICE.
DR. HOLTZ.
>>I WOULD LIKE TO THANK YOU ALL
IN OBSERVANCE OF WORLD AIDS DAY
2022.
SINCE 1988 IT'S BIN AN
OPPORTUNITY TO NOTE OUR PROGRESS
AND RECOMMIT TO OUR GOAL IN
ENDING HIV FOR PRESENT AND
FUTURE GENERATION.
GOVERNMENT AGENCIES AND HIV
ADVOCACY GROUPS AND
NON-GOVERNMENTAL ORGANIZATIONS
AND COMMUNITIES AROUND THE WORLD
OBSERVE THIS DAY TO RAISE
AWARENESS OF THE IMPORTANCE OF
HIV TESTING, PREVENTION, CARE
AND TREATMENT AND CURE TO
ADDRESS STIGMA AND
DISCRIMINATION AGAINST PEOPLE
WITH AND AT RISK FOR HIV AND
AIDS.
IT'S AN OPPORTUNITY TO ENSURE
EQUITABLE SOLUTIONS.
I THINK WE'VE SEEN THAT RESOLVE
EXHIBITED TODAY.
TO ACHIEVE THE GOAL REF DUCING
NEW HIV INFECTIONS IN THE UNITED
STATES BY AT LEAST 90% BY 2030,
THERE'S FOUR PILLARS, DIAGNOSE,
TREAT, PREVENT AND ARE RESPOND
TO POTENTIAL OUTBREAKS.
OAR CONTINUES TO WORK WITH THE
DEPARTMENT OF HEALTH AND HUMAN
SERVICES ON THIS IMPORTANT
INITIATIVE.
WE SUPPORT RESEARCH AND
EQUITABLE ACCESS AND COMMUNITY
ENGAGEMENTS.
WE HOPE TODAY'S DISCUSSION
SERVED THAT PURPOSE AND BROUGHT
NEW PERSPECTIVES.
NEXT YEAR, 2023 AS NOTED EARLIER
WILL MARK A MEANINGFUL DUAL
ANNIVERSARY.
THE OFFICE OF AIDS CREATED IN
1988 THROUGH CONGRESSIONAL
LEGISLATION WILL MARK ITS 35th
ANNIVERSARY WORKING TO IMPROVE
THE LIVES OF PEOPLE LIVING WITH
AND AFFECTED BY HIV/AIDS.
2023 ALSO MARKS THE 20th
ANNIVERSARY OF THE CREATION OF
PEPFAR SAVING AN ESTIMATED 20
MILLION LIVES.
BEFORE WE CLOSE THIS NIH
COMMEMORATION OF WORLD AIDS DAY,
I WANT TO THANK THE OFFICE OF
AIDS RESEARCH STAFF AND THE
NIH-WIDE WORLD AIDS DAY TEAM WHO
PLANNED AND PRODUCED THIS EVENT.
I AM GRATEFUL FOR THEIR
DEDICATION AND COMMITMENT TO
EXCELLENCE IN ALL THEY DO.
FINALLY, THE OFFICE OF AIDS
RESEARCH WOULD LIKE TO TAKE THIS
OPPORTUNITY TO REMEMBER THE MORE
THAN 650,000 PEOPLE WHO DIED
FROM HIV IN 2021 WORLDWIDE AND
THOSE WHO DEDICATED THEIR
CAREERS TO MAKING A DIFFERENCE
IN THE LIFE OF PEOPLE WITH HIV
AND AIDS. PLEASE STAY AFTER
THESE CLOSING REMARKS TO VIEW A
TRIBUTE TO THESE INDIVIDUALS AND
COUNTLESS OTHERS WHO LED THE WAY
ON THE ROAD TO CONQUER THE HIV
CHALLENGE. THEIR EXAMPLE
INSPIRES AND GUIDES US EVERY
DAY.
THANK YOU FOR JOINING US TODAY.